Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Clinical Guidelines |18 November 2008

Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians Free

Gerald Gartlehner, MD, MPH; Bradley N. Gaynes, MD, MPH; Richard A. Hansen, PhD, RPh; Patricia Thieda, MA; Angela DeVeaugh-Geiss, MS; Erin E. Krebs, MD, MPH; Charity G. Moore, PhD, MSPH; Laura Morgan, MA; Kathleen N. Lohr, PhD

Gerald Gartlehner, MD, MPH
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Bradley N. Gaynes, MD, MPH
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Richard A. Hansen, PhD, RPh
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Patricia Thieda, MA
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Angela DeVeaugh-Geiss, MS
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Erin E. Krebs, MD, MPH
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Charity G. Moore, PhD, MSPH
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Laura Morgan, MA
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Kathleen N. Lohr, PhD
From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
  • From Danube University, Krems, Austria; University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Indiana University School of Medicine, Roudebush Veterans Affairs Medical Center, and Regenstrief Institute, Indianapolis, Indiana; University of Pittsburgh, Pittsburgh, Pennsylvania; and RTI International, Research Triangle Park, North Carolina.

    Disclaimer: The authors of this report are responsible for its content. Statements in the report should not be construed as endorsement by the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services of a particular drug, device, test, treatment, or other clinical service.

    Acknowledgment: The authors thank Timothy S. Carey, MD, MPH, and Stacey Williams, MA, from the University of North Carolina at Chapel Hill, and also Linda Lux, MPA, and Loraine Monroe of RTI International.

    Grant Support: By a contract from the Agency for Healthcare Research and Quality to the RTI InternationalUniversity of North Carolina Evidence-based Practice Center (contract no. 290-02-0016).

    Potential Financial Conflicts of Interest:Employment: A. DeVeaugh-Geiss (GlaxoSmithKline). Consultancies: B.N. Gaynes (Pfizer, Wyeth-Ayerst, Shire Pharmaceutical). Honoraria: B.N. Gaynes (GlaxoSmithKline). Stock ownership or options (other than mutual funds): A. DeVeaugh-Geiss (GlaxoSmithKline). Expert testimony: B.N. Gaynes (Phillips Lytle). Grants received: B.N. Gaynes (Agency for Healthcare Research and Quality, National Institute of Mental Health, Bristol-Myers Squibb, Novartis, Pfizer, Robert Wood Johnson Foundation, M-3 Corporation), R.A. Hansen (GlaxoSmithKline). Grants pending: B.N. Gaynes (National Institute of Mental Health, Agency for Healthcare Research and Quality).

    Requests for Single Reprints: Gerald Gartlehner, MD, MPH, Danube University, Karl Dorrek-Strae, 3500 Krems, Austria; e-mail, gerald.gartlehner@donau-uni.ac.at.

    Current Author Addresses: Dr. Gartlehner: Danube University, Karl Dorrek-Strae, 3500 Krems, Austria.

    Dr. Gaynes: Department of Psychiatry, Campus Box 7160, University of North Carolina, Chapel Hill, NC 27599.

    Dr. Hansen: University of North Carolina, School of Pharmacy, Campus Box 7360, Chapel Hill, NC 27599.

    Ms. Thieda and Ms. Morgan: University of North Carolina, Sheps Center for Health Services Research, 725 Martin Luther King Jr. Boulevard, Chapel Hill, NC 27599.

    Ms. DeVeaugh-Geiss: University of North Carolina, Department of Epidemiology, Campus Box 7435, Chapel Hill, NC 27599.

    Dr. Krebs: Roudebush Veterans Affairs Medical Center, 1481 West 10th Street, Indianapolis, IN 46202.

    Dr. Moore: Center for Research on Health Care Data, University of Pittsburgh, 200 Meyran Avenue, Suite 300, Pittsburgh, PA 15213.

    Dr. Lohr: RTI International, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709-2194.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • Abstract
    • Methods
    • Results
    • Discussion
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

Abstract

Background:

Second-generation antidepressants dominate the management of major depressive disorder, dysthymia, and subsyndromal depression. Evidence on the comparative benefits and harms is still accruing.

Purpose:

To compare the benefits and harms of second-generation antidepressants (bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxine) for the treatment of depressive disorders in adults.

Data Sources:

MEDLINE, EMBASE, PsychLit, Cochrane Central Register of Controlled Trials, and International Pharmaceutical Abstracts from 1980 to April 2007, limited to English-language articles. Reference lists of pertinent review articles were manually searched and the Center for Drug Evaluation and Research database was explored to identify unpublished research.

Study Selection:

Abstracts and full-text articles were independently reviewed by 2 persons. Six previous good- or fair-quality systematic reviews or meta-analyses were included, as were 155 good- or fair-quality double-blind, placebo-controlled, or head-to-head randomized, controlled trials of at least 6 weeks' duration. For harms, 35 observational studies with at least 100 participants and follow-up of at least 12 weeks were also included.

Data Extraction:

Using a standard protocol, investigators abstracted data on study design and quality-related details, funding, settings, patients, and outcomes.

Data Synthesis:

If data were sufficient, meta-analyses of head-to-head trials were conducted to determine the relative benefit of response to treatment and the weighted mean differences on specific depression rating scales. If sufficient evidence was not available, adjusted indirect comparisons were conducted by using meta-regressions and network meta-analyses. Second-generation antidepressants did not substantially differ in efficacy or effectiveness for the treatment of major depressive disorder on the basis of 203 studies; however, the incidence of specific adverse events and the onset of action differed. The evidence is insufficient to draw conclusions about the comparative efficacy, effectiveness, or harms of these agents for the treatment of dysthymia and subsyndromal depression.

Limitation:

Adjusted indirect comparisons have methodological limitations and cannot conclusively rule out differences in efficacy.

Conclusion:

Current evidence does not warrant the choice of one second-generation antidepressant over another on the basis of differences in efficacy and effectiveness. Other differences with respect to onset of action and adverse events may be relevant for the choice of a medication.

Major depressive disorder (MDD) is the most prevalent axis I disorder, affecting more than 16% of U.S. adults during their lifetime (1). In 2000, the economic burden of depressive disorders was an estimated $83.1 billion (2), more than 30% of which was attributable to direct medical expenses.
Pharmacotherapy dominates the medical management of MDD. Since the mid-1980s, second-generation antidepressants have gradually replaced tricyclic antidepressants and monoamine oxidase inhibitors as first-line medications, primarily because of their lower toxicity in overdose and similar general efficacy (3). These newer treatments include selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, selective serotonin and norepinephrine reuptake inhibitors, and other second-generation drugs (Table 1).

Table 1. Second-Generation Antidepressants Approved for Use in the United States

Table 1. Second-Generation Antidepressants Approved for Use in the United States
To date, only 2 systematic reviews have assessed the comparative efficacy and harms of second-generation antidepressants (3, 4). These studies reported no substantial differences in efficacy or harms among agents. However, because of a lack of direct head-to-head comparisons, assessments in both studies were primarily qualitative. Consequently, uncertainties persist about the differences among the drugs for which sufficient head-to-head evidence is lacking.
We systematically assessed evidence on the comparative benefits and harms of second-generation antidepressants for the acute, continuation, and maintenance phases of treatment of MDD; subsyndromal depression; and dysthymia and the comparative efficacy and effectiveness for such accompanying symptoms as anxiety, insomnia, or neurovegetative symptoms. We also sought to determine whether efficacy, effectiveness, and harms differed among subgroups of patients on the basis of age, sex, race or ethnicity, or comorbid conditions.
To our knowledge, this is the first meta-analysis of second-generation antidepressants to assess quantitatively all possible comparisons among drugs in this class. We update findings of an earlier report on these pharmaceuticals (5) for the Agency for Healthcare Research and Quality.

Methods

An open process (described at www.effectivehealthcare.ahrq.gov) involving the public, the Agency for Healthcare Research and Quality's Scientific Resource Center for Effective Health Care program, and various stakeholder groups produced key questions. We followed a standardized protocol for all review steps (5).

Data Sources

We searched MEDLINE, EMBASE, PsychLit, Cochrane Central Register of Controlled Trials, and International Pharmaceutical Abstracts from 1980 to April 2007. We used Medical Subject Heading terms when available and keywords when appropriate. We combined terms for depressive disorders with a list of 12 specific second-generation antidepressantsbupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, and venlafaxineand their specific trade names. We limited electronic searches to adult 19 + years, human, and English language.
We manually searched reference lists of pertinent review articles and letters to the editor and used the Center for Drug Evaluation and Research database (up to April 2007) to identify unpublished research submitted to the U.S. Food and Drug Administration. The Scientific Resource Center invited pharmaceutical manufacturers to submit dossiers on completed research for each drug. We received dossiers from 3 pharmaceutical companies (Eli Lilly and Company, Indianapolis, Indiana; GlaxoSmithKline, Philadelphia, Pennsylvania; and Wyeth, Madison, New Jersey).

Study Selection

Two persons independently reviewed abstracts and relevant full-text articles. To assess efficacy or effectiveness regarding response, speed of onset, remission, maintenance of remission, and quality of life, we included head-to-head controlled trials of at least 6 weeks' duration that compared 1 drug with another. Because head-to-head evidence was lacking for many comparisons, we included placebo-controlled trials for indirect comparison models. To assess harms (specific adverse events, rates of adverse events, and discontinuations attributable to adverse events), we also examined data from observational studies with at least 100 participants and follow-up of at least 12 weeks. To assess differences of benefits and harms in subgroups and patients with accompanying symptoms, we reviewed both head-to-head and placebo-controlled trials. We included meta-analyses if we found them to be relevant for a key question and of good or fair methodological quality (6).
If both reviewers agreed that a study did not meet eligibility criteria, we excluded it. We also excluded studies that met eligibility criteria but were reported only as an abstract. Investigators resolved disagreements about inclusion or exclusion by consensus or by involving a third reviewer.

Data Extraction and Quality Assessment

We used a structured, Web-based data abstraction form (SRS 4.0, TrialStat, Ottawa, Ontario, Canada) onto which trained reviewers abstracted data from each study and assigned an initial quality rating. A senior reviewer read each abstracted article, evaluated completeness of data abstraction, and confirmed the quality rating. Investigators resolved disagreements by discussion and consensus or by consulting an independent party.
We assessed the internal validity (quality) of trials on the basis of predefined criteria and applied ratings of good, fair, or poor (5, 7, 8). Primary elements of quality assessment included randomization and allocation concealment, similarity of compared groups at baseline, blinding, use of intention-to-treat analysis, and overall and differential loss to follow-up. To assess observational studies, we used criteria involving selection of case patients or cohorts and control participants, adjustment for confounders, methods of outcomes assessment, length of follow-up, and statistical analysis (9). We rated studies with a fatal flaw in 1 or more categories as poor quality (Appendix Table 1) and did not include them in our analyses for this review unless no other head-to-head evidence was available. To identify effectiveness studies, we used a tool that distinguishes efficacy trials from effectiveness studies on the basis of certain elements of study design (10). Such studies have greater generalizability of results than efficacy trials because they enroll less selected study populations, use treatment modalities that mimic clinical practice, and assess health outcomes along with adverse events.
Lacking clear definitions about the equivalence of dosages among second-generation antidepressants in the published literature, we developed a roster of low, medium, and high dosages for each drug based on the interquartile dosing range (5). We used this roster, which does not indicate dosing equivalence, to detect gross inequalities in dosing that could affect comparative efficacy and effectiveness.

Appendix Table 1. Characteristics of Studies with Poor Internal Validity

Appendix Table 1. Characteristics of Studies with Poor Internal Validity

Data Synthesis

If data were sufficient, we conducted meta-analyses of head-to-head comparisons. Efficacy outcomes included the relative benefit of achieving response (more than 50% improvement from baseline), which reflects the ratio of benefits in one treatment group to benefits in another, and the weighted mean difference of changes on the Hamilton Depression Rating Scale or the Montgomery-Asberg Depression Rating Scale.
For each meta-analysis, we conducted a test of heterogeneity (I2 index) and applied both random- and fixed-effects models. We report the random-effects results because the results from both models were very similar in all meta-analyses. We assessed publication bias by using funnel plots and the Begg adjusted rank correlation test (11) based on the Kendall coefficient.
Because no head-to-head evidence was available for the majority of drug comparisons, we conducted adjusted indirect comparisons (5). We employed meta-regressions of placebo-controlled trials by using individual drugs as covariates. When the number of trials was insufficient for meta-regressions, we used modified network meta-analysis (12). Evidence suggests that indirect comparisons agree with head-to-head trials if component studies are similar and treatment effects are expected to be consistent in patients included in different trials (13), although these assumptions are usually not verifiable.
All statistical analyses used StatsDirect Statistical Software program, version 2.3.8 (StatsDirect, Sale, United Kingdom); Stata, version 9.1 (StataCorp, College Station, Texas); and SAS, version 9.1 (SAS Institute, Cary, North Carolina).

Rating the Strength of Evidence

We rated the strength of the available evidence for specific key questions and outcomes in a 3-part hierarchy (high, moderate, and low) (5) by using a modified GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach (14, 15) that incorporates 4 key elements: study design, study quality, consistency of results, and directness (availability of data on outcomes or populations of interest).

Role of Funding Source

The Agency for Healthcare Research and Quality participated in formulating the key questions and reviewed and commented on planned methods and data analysis. The Agency had no role in study selection, quality ratings, or interpretation and synthesis of the evidence, although staff reviewed interim and final evidence reports and distributed them for external peer review by outside experts.

Results

We identified 2318 citations from searches and reviews of reference lists (Figure 1). Of the 203 included studies (Appendix Tables 2 to 11), 140 (69.0%) were financially supported by pharmaceutical companies and 19 (9.3%) by governmental agencies or independent funds. For 44 (21.7%) studies, we could not determine the funding source.
Figure 1.

Study flow diagram.

The number of included articles differs from the number of included studies because some studies have multiple publications.

Appendix Table 2. Comparative Efficacy and Effectiveness Studies on Therapy for Major Depressive Disorder

Appendix Table 2. Comparative Efficacy and Effectiveness Studies on Therapy for Major Depressive Disorder

Appendix Table 3. Comparative Efficacy and Effectiveness Studies on Therapy for Dysthymia

Appendix Table 3. Comparative Efficacy and Effectiveness Studies on Therapy for Dysthymia

Appendix Table 4. Comparative Efficacy and Effectiveness Studies on Therapy for Subsyndromal Depressive Disorders

Appendix Table 4. Comparative Efficacy and Effectiveness Studies on Therapy for Subsyndromal Depressive Disorders

Appendix Table 5. Comparative Efficacy and Effectiveness Studies on Maintaining Remission and Preventing Relapse

Appendix Table 5. Comparative Efficacy and Effectiveness Studies on Maintaining Remission and Preventing Relapse

Appendix Table 6. Comparative Efficacy and Effectiveness Studies on Therapy for Recurrent and Treatment-Resistant Depression

Appendix Table 6. Comparative Efficacy and Effectiveness Studies on Therapy for Recurrent and Treatment-Resistant Depression

Appendix Table 7. Placebo-Controlled Studies of Relapse and Recurrence

Appendix Table 7. Placebo-Controlled Studies of Relapse and Recurrence

Appendix Table 8. Comparative Efficacy and Effectiveness Studies of Treatment in Adults with Major Depressive Disorder and Accompanying Symptoms

Appendix Table 8. Comparative Efficacy and Effectiveness Studies of Treatment in Adults with Major Depressive Disorder and Accompanying Symptoms

Appendix Table 9. Studies of Comparative Risk for Harms in Adults with Major Depressive Disorder

Appendix Table 9. Studies of Comparative Risk for Harms in Adults with Major Depressive Disorder

Appendix Table 10. Comparative Efficacy and Effectiveness Studies in Subgroups

Appendix Table 10. Comparative Efficacy and Effectiveness Studies in Subgroups

Appendix Table 11. Randomized, Placebo-Controlled Trials Included for Indirect Comparisons

Appendix Table 11. Randomized, Placebo-Controlled Trials Included for Indirect Comparisons

Major Depressive Disorder

Overall, we found no substantial differences in comparative efficacy and effectiveness of second-generation antidepressants for treatment of MDD (Tables 2, 3, and 4 and Figures 2, 3, and 4). This finding pertains to the acute, continuation, and maintenance phases of treatment; to patients with accompanying symptom clusters; and to subgroups defined by age, race or ethnicity, sex, or comorbid conditions (we found only sparse evidence for subgroups). Nevertheless, second-generation antidepressants are not identical drugs. They differ somewhat with respect to onset of action and frequency of some adverse events. Generally, effectiveness studies with less stringent eligibility criteria provided results similar to those of efficacy trials, indicating good generalizability of our findings to primary care populations.

Table 2. Summary of Findings on General Effectiveness

Table 2. Summary of Findings on General Effectiveness

Table 3. Summary of Findings on Adverse Events: Comparative Risk for Harms

Table 3. Summary of Findings on Adverse Events: Comparative Risk for Harms

Table 4. Summary of Findings on Effectiveness in Subgroups

Table 4. Summary of Findings on Effectiveness in Subgroups
Figure 2.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs) with other SSRIs

All estimates are based on network meta-analyses except for those marked with an asterisk or a dagger.

* Based on meta-analysis of head-to-head trials.

Based on indirect comparisons with meta-regression.

Figure 3.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs) with selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and SSRIs with serotonin and norepinephrine reuptake inhibitors (SNRIs

All estimates are based on network meta-analyses except for those marked with an asterisk or a dagger.

* Based on meta-analysis of head-to-head trials.

Based on indirect comparisons with meta-regression.

Figure 4.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SSNRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other second-generation antidepressants (ADs) with other second-generation ADs.

All estimates are based on network meta-analyses except for those marked with an asterisk.* Based on meta-analysis of head-to-head trials.

Comparative Efficacy for Acute-Phase Treatment of MDD

Eighty good- or fair-quality head-to-head, randomized, controlled trials (RCTs), comprising more than 17000 patients, compared efficacy or effectiveness for acute-phase MDD treatment. These studies provided direct evidence for 36 of 66 possible comparisons among these drugs. Only 5 trials directly compared any second-generation nonselective serotonin reuptake inhibitor with another; of these, only 1 comparison was evaluated in more than 1 trial.
For the 62 comparisons of 1 drug with another for which data were available, we conducted indirect evaluations of response rates, incorporating an additional 34 placebo-controlled trials of good or fair quality comprising 26349 patients (Appendix Table 11).
For almost all comparisons, no statistically significant differences in response rates were apparent (Figures 2, 3, and 4). For some indirect comparisons, however, the precision of estimates was low and confidence intervals encompassed differences that would be clinically significant.
Findings from some meta-analyses yielded statistically significant differences among treatments, but the modest effect sizes of the differences are probably not clinically significant (5). For example, the meta-analytic comparison of response rates to citalopram versus escitalopram (1620) yielded a statistically significant additional treatment effect for escitalopram (relative benefit favoring escitalopram, 1.14 [95% CI, 1.04 to 1.26]) (5). Pooled differences of points on the Montgomery-Asberg Depression Rating Scale presented a mean additional treatment effect (weighted mean difference) of a 1.13-point reduction (CI, 0.18 to 2.09) for escitalopram (5). A 1.13-point change on the Montgomery-Asberg Depression Rating Scale represents about one fifth to one quarter of a standard deviation, so the clinical significance of this finding may be questionable. Methods research suggests that half a standard deviation constitutes a minimally important difference for health-related quality-of-life outcomes (21).
Meta-analyses yielded significantly lower response rates for fluoxetine than for sertraline (2225) or venlafaxine (2633). The small effect sizes of the differences are probably not clinically relevant.
Eighteen trials (18, 23, 3348), mostly of fair quality, included health-related quality of life or functional capacity as secondary outcome measures. We found no differences among second-generation antidepressants for these outcomes.

Comparative Effectiveness for Acute-Phase Treatment of MDD

Three studies (23, 49, 50) can be considered effectiveness rather than efficacy trials. Their findings were consistent with those of the efficacy trials. Two fair-quality effectiveness trials indicated that improvement of health-related quality of life (work, social and physical functioning, concentration and memory, and sexual functioning) was similar for fluoxetine, paroxetine, and sertraline (23, 50).

Speed of Response

Seven fair-quality studies (39, 40, 45, 5155) reported that mirtazapine had a significantly faster onset of action than citalopram, fluoxetine, paroxetine, or sertraline after 1 or 2 weeks of treatment. All studies were supported by the manufacturer of mirtazapine. After 4 weeks of treatment, most response rates were similar. The extent to which the faster onset of mirtazapine can be extrapolated to other second-generation antidepressants is unclear. Mirtazapine and venlafaxine did not differ in speed of action (42).

Response to a Second Agent after Initial Treatment Failure

Overall, 38% of patients did not achieve a treatment response during 6 to 12 weeks of treatment with second-generation antidepressants; 54% did not achieve remission. The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial (56) provides the best evidence for assessing alternative medications among those for whom initial therapy failed. About 1 in 4 of the 727 people who participated in the switch of medications became symptom-free; this did not differ significantly among those who received sustained-release bupropion, sertraline, or extended-release venlafaxine. One open-label study (57) and a smaller efficacy study (58) reported significantly greater response rates for venlafaxine than for other second-generation drugs. Given the STAR*D findings, the clinical significance of this difference is questionable.

Maintaining Response or Remission after Treatment Success

Findings from 4 fair-quality head-to-head RCTs assessing relapse or recurrence prevention (5963) were similar for the comparisons of fluoxetine and sertraline, fluvoxamine and sertraline, duloxetine and paroxetine, and trazodone and venlafaxine. In 1 trial (59), among 105 patients who demonstrated a response at 8 weeks, 5 (10%) of 49 sertraline-treated patients and 7 (13%) of 56 of fluoxetine-treated patients had relapse over 24 weeks of continuation-phase treatment.

Efficacy or Effectiveness for Depression or Accompanying Symptoms

Clinicians may use symptom clusters that accompany depression (such as anxiety or insomnia) to guide antidepressant selection. This might improve outcomes for the depressive episode, the symptom cluster, or both. We reviewed available evidence for clinically relevant symptom clusters to address each possibility.

Treatment of Depression in Patients with Accompanying Symptom Clusters

Anxiety

Six fair-quality head-to-head trials (31, 35, 6468) suggest that antidepressants have similar antidepressive efficacy for patients with MDD and anxiety symptoms. These studies compared either fluoxetine or paroxetine with sertraline (259 patients with accompanying anxiety) (64, 65); sertraline with bupropion (972 patients; number with anxiety not provided) (6668); and sertraline with venlafaxine (20 patients with anxiety) (35). One fair-quality, 12-week trial (31) of 146 patients reported significantly greater response (75.0% vs. 49.3%) and remission rates (59.4% vs. 40.3%) with venlafaxine than with fluoxetine.

Insomnia

Two fair-quality head-to-head trials (441 patients with insomnia) (24, 69) provide limited evidence for similar efficacy of fluoxetine, nefazodone, paroxetine, or sertraline for treating depression in patients with accompanying insomnia. A pooled analysis of 3 RCTs (447 patients) (70) reported that the reduction on the Montgomery-Asberg Depression Rating Scale total score was significantly greater for patients receiving escitalopram than for those receiving citalopram (16.5 vs. 14.0); however, the clinical significance of this difference remains uncertain.

Melancholia

Two fair-quality head-to-head trials (286 patients) (28, 65) and 1 poor-quality head-to-head trial (68 patients) (71) assessed the effects of medications for treating depression in patients with melancholia. Although 2 studies reported greater response rates for sertraline than for fluoxetine (59% vs. 44%) (65) and for venlafaxine than for fluoxetine (70% vs. 50%) (71), the small sample sizes (87 and 68 patients) and high attrition rate (71) limit confidence in these findings.

Pain

We found no head-to-head evidence. Two placebo-controlled trials reported similar response rates for patients with MDD and pain who received duloxetine (72) or paroxetine (73) compared with those who received placebo.

Psychomotor Changes

The evidence is limited to subgroup analyses from 1 fair-quality head-to-head trial (65). Fluoxetine and sertraline had similar antidepressive efficacy among 47 patients with psychomotor retardation, but sertraline had higher efficacy among 78 patients with psychomotor agitation (65). Results should be interpreted cautiously because small sample sizes and multiple testing can lead to erroneous results in such subgroup analyses.

Treatment of Symptom Clusters in Patients with Accompanying Depression

Anxiety

Ten fair-quality head-to-head trials (31, 35, 40, 64, 66, 68, 7477) provide evidence that antidepressant medications do not differ substantially in efficacy for treatment of anxiety associated with MDD. Improvement of anxiety did not differ substantially among fluoxetine, paroxetine, and sertraline (549 patients) (64, 7577); sertraline and bupropion (243 patients) (66, 68); sertraline and venlafaxine (120 patients) (35); citalopram and mirtazapine (270 patients) (40); or paroxetine and nefazodone (206 patients) (74). One trial (146 patients) (31) reported significantly greater reductions in Covi Anxiety Scale scores of patients receiving venlafaxine than those receiving fluoxetine (5.7 vs. 3.9). The clinical significance of this difference remains uncertain.

Insomnia

Five fair-quality head-to-head trials (24, 37, 45, 62, 69) and a pooled analysis of 3 RCTs (70) involving 1540 patients provide limited evidence about the comparative effects of antidepressants on insomnia in patients with depression. Individual trials favored escitalopram over citalopram (70), nefazodone over fluoxetine (69), and trazodone over fluoxetine (37) and venlafaxine (62) in improving sleep scores. The comparisons were limited to single studies, and it is difficult to assess the clinical significance of these findings.

Pain

Three fair-quality head-to-head trials (63, 78, 79) and 1 poor-quality trial (80) compared duloxetine with paroxetine. These trials (1466 patients) found no substantial difference in pain relief between duloxetine and paroxetine.

Somatization

A fair-quality, 9-month open-label effectiveness trial reported similar improvement of somatization among 573 patients receiving fluoxetine, paroxetine, or sertraline (50).

Risk for Harms

We analyzed adverse events data from 80 head-to-head efficacy studies and 42 additional studies of both experimental and observational designs. Methods of adverse events assessment in efficacy trials differed greatly. Few studies used objective scales. Determining whether assessment methods were unbiased and adequate was often difficult.

Adverse Events Profiles

Constipation, diarrhea, dizziness, headache, insomnia, nausea, sexual adverse events, and somnolence were commonly and consistently reported adverse events. On average, 61% of patients in efficacy trials experienced at least 1 adverse event. Nausea and vomiting were the most common reasons for discontinuation in efficacy studies.
Overall, second-generation antidepressants had similar adverse events profiles. Table 5 summarizes some differences in the incidence of specific adverse events.

Table 5. Main Differences in Specific Adverse Events

Table 5. Main Differences in Specific Adverse Events

Sexual Dysfunction

A fair-quality prospective observational study (1022 patients) from Spain reported that 59% of patients treated with second-generation antidepressants experienced sexual dysfunction (81). On the basis of 5 RCTs (1489 patients), bupropion led to a significantly lower rate of sexual adverse events than fluoxetine and sertraline (8286). Paroxetine frequently led to higher rates of sexual dysfunction than did fluoxetine, fluvoxamine, nefazodone, or sertraline (16% vs. 6%) (24, 76, 87, 88). Underreporting of absolute rates of sexual dysfunction is likely in these studies.

Suicidality

Eleven studies (8999) assessed the risk for suicidality (suicidal thinking or behavior) in patients treated with second-generation antidepressants; comparative data are sparse. No particular drug has an excess risk compared with any other drug in this class (94, 98). These findings are based primarily on retrospective cohort studies (91, 93, 94, 98). Confounding by indication (patients at higher risk for suicide being prescribed certain medications rather than others) may have led to erroneous conclusions.
The United Kingdom's Committee on Safety of Medicines conducted the largest attempt to determine whether second-generation antidepressants increase the risk for suicidality in 2004 (89). A good meta-analysis of placebo-controlled trials of selective serotonin reuptake inhibitors, comprising more than 40000 adults, yielded no evidence that these agents increase the risk for suicide (odds ratio, 0.85 [CI, 0.20 to 3.40]) but did reveal an increased risk for nonfatal suicide attempts (odds ratio, 1.57 [CI, 0.99 to 2.55]) (92).
Another good meta-analysis of published trial data (90), comprising more than 87000 patients, reported a significantly higher risk for suicide attempts among patients receiving selective serotonin reuptake inhibitors than among those receiving placebo (odds ratio, 2.25 [CI, 1.14 to 4.55]). This study estimated the overall rate of suicide attempts as 3.9 (CI, 3.3 to 4.6) per 1000 patients treated with these drugs, with an incidence of 18.2 suicide attempts per 1000 patient-years.

Other Severe Adverse Events

Evidence on the comparative risk for rare but severe adverse events, such as seizures, cardiovascular events (events relating to systolic and diastolic blood pressure and pulse or heart rate), hyponatremia, hepatotoxicity, and the serotonin syndrome, is insufficient to draw firm conclusions. Clinicians should keep in mind the risk for such harms when treating patients with a second-generation antidepressant.

Treatment of MDD in Subgroups

No study directly compared efficacy, effectiveness, and harms of second-generation antidepressants between subgroups and the general population for treatment of depression syndromes. Numerous studies, however, conducted subgroup analyses or used subgroups as the study population.

Age

Multiple head-to-head trials (22, 44, 48, 50, 54, 100107) and 2 fair-quality meta-analyses (108, 109) indicated that the efficacy of second-generation antidepressants does not differ in elderly patients (65 to 80 years of age) or very elderly patients (##gt##80 years of age) compared with younger patients. These findings are consistent with placebo-controlled trials (110116) conducted in elderly or very elderly patients, which reported effect sizes similar to those from trials in younger patients.

Sex

Efficacy trials did not show differences between men and women (108, 109, 117). Observational evidence supports this conclusion (118).

Race or Ethnicity

One trial that evaluated efficacy differences in racial subgroups (119) did not show any differences, but this trial was rated poor quality because it lacked an intention-to-treat analysis.

Comorbid Conditions

No study directly compared efficacy, effectiveness, and harms of second-generation antidepressants between depressed patients with comorbid conditions and the general population.
One poor-quality head-to-head study did not detect differences in efficacy and tolerability among fluoxetine, paroxetine, or sertraline in depressed individuals with HIV or AIDS (120).
Seventeen placebo-controlled trials of varying quality (119, 121136) and 1 fair-quality systematic review (137) evaluated second-generation antidepressants in patients with various comorbid conditions. Some studies suggested that these drugs may not be efficacious for depressed patients with such comorbid conditions as HIV or AIDS (119, 121, 122), alcohol abuse (123125), Alzheimer disease (127), stroke (133, 134), or substance abuse (135, 136). Many of the studies were not powered to detect a meaningful difference between active treatment and placebo.

Dysthymia

Dysthymia is a chronic depressive disorder that is characterized by depressed mood for more days than not for at least 2 years (138). We found no head-to-head trial that studied patients with dysthymia. One good-quality trial (38) and 4 fair-quality placebo-controlled trials (36, 43, 139142) provide mixed evidence on the general efficacy and effectiveness of fluoxetine, paroxetine, and sertraline for the treatment of dysthymia.

Subsyndromal Depression

Subsyndromal depression (also called minor depression) is a mood disturbance of at least 2 weeks' duration with fewer symptoms of depression than MDD (138). One nonrandomized, open-label trial (100) compared citalopram with sertraline but found no difference in efficacy. Findings from 2 placebo-controlled trials (141143) were insufficient to draw any conclusions about comparative efficacy and effectiveness of second-generation antidepressants for the treatment of subsyndromal depression.

Discussion

In this systematic review of data from 203 studies, direct and indirect comparisons yielded no substantial differences in efficacy for the treatment of MDD. Statistically significant results were small and are unlikely to have clinical significance.
Existing evidence on efficacy does not warrant the choice of one second-generation antidepressant over another, although we could not conclusively establish equivalence in efficacy for many comparisons. No differences in efficacy were apparent for patients with accompanying symptoms or subgroups based on age, sex, race or ethnicity, or comorbid conditions, although evidence within subgroups was limited.
Nevertheless, second-generation antidepressants cannot be considered identical drugs. Moderate-strength evidence supports some differences among individual drugs with respect to speed of onset of response and incidence of some adverse events. For example, consistent evidence from multiple trials demonstrated that mirtazapine has a faster onset of action than citalopram, fluoxetine, paroxetine, or sertraline (39, 45, 5255) and that bupropion has fewer sexual adverse events than fluoxetine, paroxetine, or sertraline (82, 86, 144). These differences may be clinically significant and may influence medication choice for a given patient.
Across all efficacy trials, more than 50% of patients treated with second-generation antidepressants for acute-phase depression did not achieve remission, the primary goal of depression treatment. Almost 40% did not achieve response, a less rigorous outcome. Current evidence is insufficient to identify patient factors that can reliably predict response or nonresponse to an individual drug. Although limited evidence indicates that the efficacy of second-generation antidepressants is similar among patients for whom treatment with a first-line agent failed, a substantial proportion of these patients do not achieve response or remission with second-line treatment (56). Multiple treatment options are required for patients who do not respond to first- or second-line treatment.
Our statistical comparisons confirm the results of previous systematic reviews (3, 4, 145), although our interpretation of findings differs from that of Cipriani and colleagues (145) in their recent meta-analysis comparing fluoxetine with other antidepressants. Their pooled estimates of response rates for fluoxetine compared with sertraline and venlafaxine were slightly larger than our results. These differences might be attributable to their inclusion of open-label trials or their use of odds ratios, which overestimate differences when event rates are high. As in our study, the effect size meta-analysis by Cipriani and colleagues did not reach statistical significance, but they interpreted these differences as clinically significant.
Our review has several limitations. First, most of the studies were efficacy trials conducted in highly selected populations. The applicability of their results to the average patient with acute MDD might be limited. However, the fact that the effectiveness trial results (23, 49, 50) were consistent with the efficacy study results strengthens our findings.
Indirect comparisons have methodological limitations, most notably a lack of power that resulted in wide confidence intervals, which can encompass clinically significant differences between treatments. Nevertheless, we believe that the consistent similarity of treatment effects across all comparisons supports our conclusion that no substantial differences exist.
Publication bias is a concern for all systematic reviews. Selective availability of studies with positive results can seriously bias conclusions, particularly when a pharmaceutical company compares 2 of its own drugs (as in the case of citalopram and escitalopram). Selective reporting is conceivable; however, we found no evidence to prove publication bias. The validity of statistical methods to explore publication bias, such as funnel plots, is limited because of the small number of studies for individual comparisons.
Although our review included more than 200 studies, many questions remain. More evidence is needed on the most appropriate duration of antidepressant treatment for maintaining response and remission. Future studies should evaluate whether different formulations (for example, controlled release vs. immediate release) lead to differences in adherence and subsequent relapse or recurrence. In addition, although most trials maintained the dose used in acute-phase treatment throughout the continuation and maintenance phases of treatment, little is known about how drug dose affects the risk for relapse or recurrence. Future research is also needed to reliably establish the general efficacy of second-generation antidepressants for the treatment of dysthymia and subsyndromal depression.
How do our findingsthat pharmacologic differences between second-generation antidepressants do not translate into substantial clinical differences, although tolerability may differinform the practicing clinician? Given the difficulty in predicting what medication will be both efficacious for and tolerated by an individual patient, familiarity with a broad spectrum of antidepressants is prudent. An emphasis on providing treatment trials of adequate dose and duration, with recent evidence providing support for maximum but tolerable doses for at least 8 weeks (146), seems at least as important as the choice of specific drug.

References

  1. Kessler
    RC
    ,  
    Berglund
    P
    ,  
    Demler
    O
    ,  
    Jin
    R
    ,  
    Merikangas
    KR
    ,  
    Walters
    EE
    .  
    Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.
    Arch Gen Psychiatry
    2005
    62
    593
    602
    PubMed
    CrossRef
    PubMed
  2. Greenberg
    PE
    ,  
    Kessler
    RC
    ,  
    Birnbaum
    HG
    ,  
    Leong
    SA
    ,  
    Lowe
    SW
    ,  
    Berglund
    PA
    .  
    The economic burden of depression in the United States: how did it change between 1990 and 2000?
    J Clin Psychiatry
    2003
    64
    1465
    75
    PubMed
    CrossRef
    PubMed
  3. Williams
    JW
    Jr
    ,  
    Mulrow
    CD
    ,  
    Chiquette
    E
    ,  
    Nol
    PH
    ,  
    Aguilar
    C
    ,  
    Cornell
    J
    .  
    A systematic review of newer pharmacotherapies for depression in adults: evidence report summary.
    Ann Intern Med
    2000
    132
    743
    56
    CrossRef
    PubMed
  4. Hansen
    RA
    ,  
    Gartlehner
    G
    ,  
    Lohr
    KN
    ,  
    Gaynes
    BN
    ,  
    Carey
    TS
    .  
    Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
    Ann Intern Med
    2005
    143
    415
    26
    CrossRef
    PubMed
  5. Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, et al. Comparative Effectiveness of Second-generation Antidepressants in the Pharmacologic Treatment of Adult Depression. Comparative Effectiveness Review No. 7-EHC007-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2007. Accessed at www.effectivehealthcare.ahrq.gov/reports/final.cfm on 30 September 2008.
  6. Balk
    EM
    ,  
    Lau
    J
    ,  
    Bonis
    PA
    .  
    Reading and critically appraising systematic reviews and meta-analyses: a short primer with a focus on hepatology.
    J Hepatol
    2005
    43
    729
    36
    PubMed
    CrossRef
    PubMed
  7. Harris
    RP
    ,  
    Helfand
    M
    ,  
    Woolf
    SH
    ,  
    Lohr
    KN
    ,  
    Mulrow
    CD
    ,  
    Teutsch
    SM
    .  
    Methods Work Group
    Third US Preventive Services Task Force
    Current methods of the US Preventive Services Task Force: a review of the process.
    Am J Prev Med
    2001
    20
    21
    35
    PubMed
    CrossRef
    PubMed
  8. Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4. 2nd ed. York, United Kingdom: Univ of York; 2001. Accessed at www.york.ac.uk/inst/crd/report4.htm on 3 October 2008.
  9. Deeks
    JJ
    ,  
    Dinnes
    J
    ,  
    D'Amico
    R
    ,  
    Sowden
    AJ
    ,  
    Sakarovitch
    C
    ,  
    Song
    F
    .  
    International Stroke Trial Collaborative Group
    Evaluating non-randomised intervention studies.
    Health Technol Assess
    2003
    7
    iii
    x, 1-173
    PubMed
    CrossRef
    PubMed
  10. Gartlehner
    G
    ,  
    Hansen
    RA
    ,  
    Nissman
    D
    ,  
    Lohr
    KN
    ,  
    Carey
    TS
    .  
    A simple and valid tool distinguished efficacy from effectiveness studies.
    J Clin Epidemiol
    2006
    59
    1040
    8
    PubMed
    CrossRef
    PubMed
  11. Begg
    CB
    ,  
    Mazumdar
    M
    .  
    Operating characteristics of a rank correlation test for publication bias.
    Biometrics
    1994
    50
    1088
    101
    PubMed
    CrossRef
    PubMed
  12. Lumley
    T
    .  
    Network meta-analysis for indirect treatment comparisons.
    Stat Med
    2002
    21
    2313
    24
    PubMed
    CrossRef
    PubMed
  13. Glenny
    AM
    ,  
    Altman
    DG
    ,  
    Song
    F
    ,  
    Sakarovitch
    C
    ,  
    Deeks
    JJ
    ,  
    D'Amico
    R
    .  
    International Stroke Trial Collaborative Group
    Indirect comparisons of competing interventions.
    Health Technol Assess
    2005
    9
    1
    134, iii-iv
    PubMed
    CrossRef
    PubMed
  14. Atkins
    D
    ,  
    Eccles
    M
    ,  
    Flottorp
    S
    ,  
    Guyatt
    GH
    ,  
    Henry
    D
    ,  
    Hill
    S
    .  
    GRADE Working Group
    Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group.
    BMC Health Serv Res
    2004
    4
    38
    PubMed
    CrossRef
    PubMed
  15. Guyatt
    G
    ,  
    Gutterman
    D
    ,  
    Baumann
    MH
    ,  
    Addrizzo-Harris
    D
    ,  
    Hylek
    EM
    ,  
    Phillips
    B
    .  
    Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force.
    Chest
    2006
    129
    174
    81
    PubMed
    CrossRef
    PubMed
  16. Lepola
    UM
    ,  
    Loft
    H
    ,  
    Reines
    EH
    .  
    Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Int Clin Psychopharmacol
    2003
    18
    211
    7
    PubMed
    CrossRef
    PubMed
  17. Colonna
    L
    ,  
    Andersen
    HF
    ,  
    Reines
    EH
    .  
    A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Curr Med Res Opin
    2005
    21
    1659
    68
    PubMed
    CrossRef
    PubMed
  18. Burke
    WJ
    ,  
    Gergel
    I
    ,  
    Bose
    A
    .  
    Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    J Clin Psychiatry
    2002
    63
    331
    6
    PubMed
    CrossRef
    PubMed
  19. Moore
    N
    ,  
    Verdoux
    H
    ,  
    Fantino
    B
    .  
    Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder.
    Int Clin Psychopharmacol
    2005
    20
    131
    7
    PubMed
    CrossRef
    PubMed
  20. FDA Center for Drug Evaluation and Research. Statistical Review of NDA 21-323 (Escitalopram Oxalate). Rockville, MD: U.S. Food and Drug Administration; 2001. Accessed at www.fda.gov/cder/foi/nda/2002/21-323.pdf_Lexapro_Statr.pdf on 3 October 2008.
  21. Norman
    GR
    ,  
    Sloan
    JA
    ,  
    Wyrwich
    KW
    .  
    Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.
    Med Care
    2003
    41
    582
    92
    PubMed
    PubMed
  22. Newhouse
    PA
    ,  
    Krishnan
    KR
    ,  
    Doraiswamy
    PM
    ,  
    Richter
    EM
    ,  
    Batzar
    ED
    ,  
    Clary
    CM
    .  
    A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.
    J Clin Psychiatry
    2000
    61
    559
    68
    PubMed
    CrossRef
    PubMed
  23. Sechter
    D
    ,  
    Troy
    S
    ,  
    Paternetti
    S
    ,  
    Boyer
    P
    .  
    A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    Eur Psychiatry
    1999
    14
    41
    8
    PubMed
    CrossRef
    PubMed
  24. Fava
    M
    ,  
    Hoog
    SL
    ,  
    Judge
    RA
    ,  
    Kopp
    JB
    ,  
    Nilsson
    ME
    ,  
    Gonzales
    JS
    .  
    Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
    J Clin Psychopharmacol
    2002
    22
    137
    47
    PubMed
    CrossRef
    PubMed
  25. Bennie
    EH
    ,  
    Mullin
    JM
    ,  
    Martindale
    JJ
    .  
    A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
    J Clin Psychiatry
    1995
    56
    229
    37
    PubMed
    PubMed
  26. Costa e Silva
    J
    .  
    Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
    J Clin Psychiatry
    1998
    59
    352
    7
    PubMed
    CrossRef
    PubMed
  27. Alves
    C
    ,  
    Cachola
    I
    ,  
    Brandao
    J
    .  
    Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression.
    Primary Care Psychiatry
    1999
    5
    57
    63
  28. Tzanakaki
    M
    ,  
    Guazzelli
    M
    ,  
    Nimatoudis
    I
    ,  
    Zissis
    NP
    ,  
    Smeraldi
    E
    ,  
    Rizzo
    F
    .  
    Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia.
    Int Clin Psychopharmacol
    2000
    15
    29
    34
    PubMed
    CrossRef
    PubMed
  29. Tylee
    A
    ,  
    Beaumont
    G
    ,  
    Bowden
    MW
    ,  
    Reynolds
    A
    .  
    A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice.
    Primary Care Psychiatry
    1997
    3
    51
    8
  30. Rudolph
    RL
    ,  
    Feiger
    AD
    .  
    A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    J Affect Disord
    1999
    56
    171
    81
    PubMed
    CrossRef
    PubMed
  31. De Nayer
    A
    ,  
    Geerts
    S
    ,  
    Ruelens
    L
    ,  
    Schittecatte
    M
    ,  
    De Bleeker
    E
    ,  
    Van Eeckhoutte
    I
    .  
    Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
    Int J Neuropsychopharmacol
    2002
    5
    115
    20
    PubMed
    CrossRef
    PubMed
  32. Dierick
    M
    ,  
    Ravizza
    L
    ,  
    Realini
    R
    ,  
    Martin
    A
    .  
    A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients.
    Prog Neuropsychopharmacol Biol Psychiatry
    1996
    20
    57
    71
    PubMed
    CrossRef
    PubMed
  33. Nemeroff
    CB
    ,  
    Thase
    ME
    .  
    EPIC 014 Study Group
    A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
    J Psychiatr Res
    2007
    41
    351
    9
    PubMed
    CrossRef
    PubMed
  34. Aberg-Wistedt
    A
    ,  
    Agren
    H
    ,  
    Ekselius
    L
    ,  
    Bengtsson
    F
    ,  
    Akerblad
    AC
    .  
    Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
    J Clin Psychopharmacol
    2000
    20
    645
    52
    PubMed
    CrossRef
    PubMed
  35. Sir
    A
    ,  
    D'Souza
    RF
    ,  
    Uguz
    S
    ,  
    George
    T
    ,  
    Vahip
    S
    ,  
    Hopwood
    M
    .  
    Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
    J Clin Psychiatry
    2005
    66
    1312
    20
    PubMed
    CrossRef
    PubMed
  36. Ravindran
    AV
    ,  
    Guelfi
    JD
    ,  
    Lane
    RM
    ,  
    Cassano
    GB
    .  
    Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression.
    J Clin Psychiatry
    2000
    61
    821
    7
    PubMed
    CrossRef
    PubMed
  37. Beasley
    CM
    Jr
    ,  
    Dornseif
    BE
    ,  
    Pultz
    JA
    ,  
    Bosomworth
    JC
    ,  
    Sayler
    ME
    .  
    Fluoxetine versus trazodone: efficacy and activating-sedating effects.
    J Clin Psychiatry
    1991
    52
    294
    9
    PubMed
    PubMed
  38. Devanand
    DP
    ,  
    Nobler
    MS
    ,  
    Cheng
    J
    ,  
    Turret
    N
    ,  
    Pelton
    GH
    ,  
    Roose
    SP
    .  
    Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder.
    Am J Geriatr Psychiatry
    2005
    13
    59
    68
    PubMed
    CrossRef
    PubMed
  39. Wheatley
    DP
    ,  
    van Moffaert
    M
    ,  
    Timmerman
    L
    ,  
    Kremer
    CM
    .  
    Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
    J Clin Psychiatry
    1998
    59
    306
    12
    PubMed
    CrossRef
    PubMed
  40. Leinonen
    E
    ,  
    Skarstein
    J
    ,  
    Behnke
    K
    ,  
    Agren
    H
    ,  
    Helsdingen
    JT
    .  
    Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
    Int Clin Psychopharmacol
    1999
    14
    329
    37
    PubMed
    CrossRef
    PubMed
  41. McPartlin
    GM
    ,  
    Reynolds
    A
    ,  
    Anderson
    C
    ,  
    Casoy
    J
    .  
    A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice.
    Primary Care Psychiatry
    1998
    127
    32
  42. Guelfi
    JD
    ,  
    Ansseau
    M
    ,  
    Timmerman
    L
    ,  
    Krsgaard
    S
    .  
    Mirtazapine-Venlafaxine Study Group
    Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features.
    J Clin Psychopharmacol
    2001
    21
    425
    31
    PubMed
    CrossRef
    PubMed
  43. Vanelle
    JM
    ,  
    Attar-Levy
    D
    ,  
    Poirier
    MF
    ,  
    Bouhassira
    M
    ,  
    Blin
    P
    ,  
    Oli
    JP
    .  
    Controlled efficacy study of fluoxetine in dysthymia.
    Br J Psychiatry
    1997
    170
    345
    50
    PubMed
    CrossRef
    PubMed
  44. Weihs
    KL
    ,  
    Settle
    EC
    Jr
    ,  
    Batey
    SR
    ,  
    Houser
    TL
    ,  
    Donahue
    RM
    ,  
    Ascher
    JA
    .  
    Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
    J Clin Psychiatry
    2000
    61
    196
    202
    PubMed
    CrossRef
    PubMed
  45. Versiani
    M
    ,  
    Moreno
    R
    ,  
    Ramakers-van Moorsel
    CJ
    ,  
    Schutte
    AJ
    .  
    Comparative Efficacy Antidepressants Study Group
    Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.
    CNS Drugs
    2005
    19
    137
    46
    PubMed
    CrossRef
    PubMed
  46. Boyer
    P
    ,  
    Danion
    JM
    ,  
    Bisserbe
    JC
    ,  
    Hotton
    JM
    ,  
    Troy
    S
    .  
    Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression. A 6-month double-blind study in a primary-care setting in France.
    Pharmacoeconomics
    1998
    13
    157
    69
    PubMed
    CrossRef
    PubMed
  47. Bielski
    RJ
    ,  
    Ventura
    D
    ,  
    Chang
    CC
    .  
    A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
    J Clin Psychiatry
    2004
    65
    1190
    6
    PubMed
    CrossRef
    PubMed
  48. Finkel
    SI
    ,  
    Richter
    EM
    ,  
    Clary
    CM
    ,  
    Batzar
    E
    .  
    Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.
    Am J Geriatr Psychiatry
    1999
    7
    221
    7
    PubMed
    CrossRef
    PubMed
  49. Ekselius
    L
    ,  
    von Knorring
    L
    ,  
    Eberhard
    G
    .  
    A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
    Int Clin Psychopharmacol
    1997
    12
    323
    31
    PubMed
    CrossRef
    PubMed
  50. Kroenke
    K
    ,  
    West
    SL
    ,  
    Swindle
    R
    ,  
    Gilsenan
    A
    ,  
    Eckert
    GJ
    ,  
    Dolor
    R
    .  
    Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
    JAMA
    2001
    286
    2947
    55
    PubMed
    CrossRef
    PubMed
  51. Hong
    CJ
    ,  
    Hu
    WH
    ,  
    Chen
    CC
    ,  
    Hsiao
    CC
    ,  
    Tsai
    SJ
    ,  
    Ruwe
    FJ
    .  
    A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
    J Clin Psychiatry
    2003
    64
    921
    6
    PubMed
    CrossRef
    PubMed
  52. Benkert
    O
    ,  
    Szegedi
    A
    ,  
    Kohnen
    R
    .  
    Mirtazapine compared with paroxetine in major depression.
    J Clin Psychiatry
    2000
    61
    656
    63
    PubMed
    CrossRef
    PubMed
  53. Szegedi
    A
    ,  
    Mller
    MJ
    ,  
    Anghelescu
    I
    ,  
    Klawe
    C
    ,  
    Kohnen
    R
    ,  
    Benkert
    O
    .  
    Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression.
    J Clin Psychiatry
    2003
    64
    413
    20
    PubMed
    CrossRef
    PubMed
  54. Schatzberg
    AF
    ,  
    Kremer
    C
    ,  
    Rodrigues
    HE
    ,  
    Murphy
    GM
    Jr
    .  
    Mirtazapine vs. Paroxetine Study Group
    Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
    Am J Geriatr Psychiatry
    2002
    10
    541
    50
    PubMed
    CrossRef
    PubMed
  55. Behnke
    K
    ,  
    Sgaard
    J
    ,  
    Martin
    S
    ,  
    Buml
    J
    ,  
    Ravindran
    AV
    ,  
    Agren
    H
    .  
    Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study.
    J Clin Psychopharmacol
    2003
    23
    358
    64
    PubMed
    CrossRef
    PubMed
  56. Rush
    AJ
    ,  
    Trivedi
    MH
    ,  
    Wisniewski
    SR
    ,  
    Stewart
    JW
    ,  
    Nierenberg
    AA
    ,  
    Thase
    ME
    .  
    STAR*D Study Team
    Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    N Engl J Med
    2006
    354
    1231
    42
    PubMed
    CrossRef
    PubMed
  57. Baldomero
    EB
    ,  
    Ubago
    JG
    ,  
    Cercs
    CL
    ,  
    Ruiloba
    JV
    ,  
    Calvo
    CG
    ,  
    Lpez
    RP
    .  
    Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study.
    Depress Anxiety
    2005
    22
    68
    76
    PubMed
    CrossRef
    PubMed
  58. Poirier
    MF
    ,  
    Boyer
    P
    .  
    Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.
    Br J Psychiatry
    1999
    175
    12
    6
    PubMed
    CrossRef
    PubMed
  59. van Moffaert
    M
    ,  
    Bartholome
    F
    ,  
    Cosyns
    P
    ,  
    De Nayer
    AR
    .  
    A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression.
    Hum Psychopharmacol
    1995
    10
    393
    405
    CrossRef
  60. Franchini
    L
    ,  
    Gasperini
    M
    ,  
    Perez
    J
    ,  
    Smeraldi
    E
    ,  
    Zanardi
    R
    .  
    A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression.
    J Clin Psychiatry
    1997
    58
    104
    7
    PubMed
    CrossRef
    PubMed
  61. Franchini
    L
    ,  
    Gasperini
    M
    ,  
    Zanardi
    R
    ,  
    Smeraldi
    E
    .  
    Four-year follow-up study of sertraline and fluvoxamine in long-term treatment of unipolar subjects with high recurrence rate.
    J Affect Disord
    2000
    58
    233
    6
    PubMed
    CrossRef
    PubMed
  62. Cunningham
    LA
    ,  
    Borison
    RL
    ,  
    Carman
    JS
    ,  
    Chouinard
    G
    ,  
    Crowder
    JE
    ,  
    Diamond
    BI
    .  
    A comparison of venlafaxine, trazodone, and placebo in major depression.
    J Clin Psychopharmacol
    1994
    14
    99
    106
    PubMed
    CrossRef
    PubMed
  63. Perahia
    DG
    ,  
    Wang
    F
    ,  
    Mallinckrodt
    CH
    ,  
    Walker
    DJ
    ,  
    Detke
    MJ
    .  
    Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Eur Psychiatry
    2006
    21
    367
    78
    PubMed
    CrossRef
    PubMed
  64. Fava
    M
    ,  
    Rosenbaum
    JF
    ,  
    Hoog
    SL
    ,  
    Tepner
    RG
    ,  
    Kopp
    JB
    ,  
    Nilsson
    ME
    .  
    Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
    J Affect Disord
    2000
    59
    119
    26
    PubMed
    CrossRef
    PubMed
  65. Flament
    MF
    ,  
    Lane
    RM
    ,  
    Zhu
    R
    ,  
    Ying
    Z
    .  
    Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Int Clin Psychopharmacol
    1999
    14
    259
    75
    PubMed
    CrossRef
    PubMed
  66. Rush
    AJ
    ,  
    Trivedi
    MH
    ,  
    Carmody
    TJ
    ,  
    Donahue
    RM
    ,  
    Houser
    TL
    ,  
    Bolden-Watson
    C
    .  
    Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.
    Neuropsychopharmacology
    2001
    25
    131
    8
    PubMed
    CrossRef
    PubMed
  67. Rush
    AJ
    ,  
    Batey
    SR
    ,  
    Donahue
    RM
    ,  
    Ascher
    JA
    ,  
    Carmody
    TJ
    ,  
    Metz
    A
    .  
    Does pretreatment anxiety predict response to either bupropion SR or sertraline?
    J Affect Disord
    2001
    64
    81
    7
    PubMed
    CrossRef
    PubMed
  68. Trivedi
    MH
    ,  
    Rush
    AJ
    ,  
    Carmody
    TJ
    ,  
    Donahue
    RM
    ,  
    Bolden-Watson
    C
    ,  
    Houser
    TL
    .  
    Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?
    J Clin Psychiatry
    2001
    62
    776
    81
    PubMed
    CrossRef
    PubMed
  69. Rush
    AJ
    ,  
    Armitage
    R
    ,  
    Gillin
    JC
    ,  
    Yonkers
    KA
    ,  
    Winokur
    A
    ,  
    Moldofsky
    H
    .  
    Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
    Biol Psychiatry
    1998
    44
    3
    14
    PubMed
    CrossRef
    PubMed
  70. Lader
    M
    ,  
    Andersen
    HF
    ,  
    Baekdal
    T
    .  
    The effect of escitalopram on sleep problems in depressed patients.
    Hum Psychopharmacol
    2005
    20
    349
    54
    PubMed
    CrossRef
    PubMed
  71. Clerc
    GE
    ,  
    Ruimy
    P
    ,  
    Verdeau-Palls
    J
    .  
    A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group.
    Int Clin Psychopharmacol
    1994
    9
    139
    43
    PubMed
    CrossRef
    PubMed
  72. Brannan
    SK
    ,  
    Mallinckrodt
    CH
    ,  
    Brown
    EB
    ,  
    Wohlreich
    MM
    ,  
    Watkin
    JG
    ,  
    Schatzberg
    AF
    .  
    Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    J Psychiatr Res
    2005
    39
    43
    53
    PubMed
    CrossRef
    PubMed
  73. Dickens
    C
    ,  
    Jayson
    M
    ,  
    Sutton
    C
    ,  
    Creed
    F
    .  
    The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain.
    Psychosomatics
    2000
    41
    490
    9
    PubMed
    CrossRef
    PubMed
  74. Baldwin
    DS
    ,  
    Hawley
    CJ
    ,  
    Abed
    RT
    ,  
    Maragakis
    BP
    ,  
    Cox
    J
    ,  
    Buckingham
    SA
    .  
    A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    J Clin Psychiatry
    1996
    57
    46
    52
    PubMed
    PubMed
  75. Chouinard
    G
    ,  
    Saxena
    B
    ,  
    Blanger
    MC
    ,  
    Ravindran
    A
    ,  
    Bakish
    D
    ,  
    Beauclair
    L
    .  
    A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    J Affect Disord
    1999
    54
    39
    48
    PubMed
    CrossRef
    PubMed
  76. Fava
    M
    ,  
    Amsterdam
    JD
    ,  
    Deltito
    JA
    ,  
    Salzman
    C
    ,  
    Schwaller
    M
    ,  
    Dunner
    DL
    .  
    A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
    Ann Clin Psychiatry
    1998
    10
    145
    50
    PubMed
    CrossRef
    PubMed
  77. Gagiano
    CA
    .  
    A double blind comparison of paroxetine and fluoxetine in patients with major depression.
    Br J Clin Res
    1993
    4
    145
    52
  78. Detke
    MJ
    ,  
    Wiltse
    CG
    ,  
    Mallinckrodt
    CH
    ,  
    McNamara
    RK
    ,  
    Demitrack
    MA
    ,  
    Bitter
    I
    .  
    Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Eur Neuropsychopharmacol
    2004
    14
    457
    70
    PubMed
    CrossRef
    PubMed
  79. Clinical Study Summary: Study F1J-MC-HMAT Study Group A. Indianapolis, IN: Eli Lilly; 2004. Accessed at www.clinicalstudyresults.org/drugdetails/?unique_id=4091a##amp##sort=c.company_name##amp##page=1##amp##drug_id=170 on 30 September 2008.
  80. Goldstein
    DJ
    ,  
    Lu
    Y
    ,  
    Detke
    MJ
    ,  
    Wiltse
    C
    ,  
    Mallinckrodt
    C
    ,  
    Demitrack
    MA
    .  
    Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine.
    J Clin Psychopharmacol
    2004
    24
    389
    99
    PubMed
    CrossRef
    PubMed
  81. Montejo
    AL
    ,  
    Llorca
    G
    ,  
    Izquierdo
    JA
    ,  
    Rico-Villademoros
    F
    .  
    Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
    J Clin Psychiatry
    2001
    62
    10
    21
    PubMed
    PubMed
  82. Coleman
    CC
    ,  
    King
    BR
    ,  
    Bolden-Watson
    C
    ,  
    Book
    MJ
    ,  
    Segraves
    RT
    ,  
    Richard
    N
    .  
    A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
    Clin Ther
    2001
    23
    1040
    58
    PubMed
    CrossRef
    PubMed
  83. Segraves
    RT
    ,  
    Kavoussi
    R
    ,  
    Hughes
    AR
    ,  
    Batey
    SR
    ,  
    Johnston
    JA
    ,  
    Donahue
    R
    .  
    Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment.
    J Clin Psychopharmacol
    2000
    20
    122
    8
    PubMed
    CrossRef
    PubMed
  84. Coleman
    CC
    ,  
    Cunningham
    LA
    ,  
    Foster
    VJ
    ,  
    Batey
    SR
    ,  
    Donahue
    RM
    ,  
    Houser
    TL
    .  
    Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.
    Ann Clin Psychiatry
    1999
    11
    205
    15
    PubMed
    CrossRef
    PubMed
  85. Croft
    H
    ,  
    Settle
    E
    Jr
    ,  
    Houser
    T
    ,  
    Batey
    SR
    ,  
    Donahue
    RM
    ,  
    Ascher
    JA
    .  
    A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
    Clin Ther
    1999
    21
    643
    58
    PubMed
    CrossRef
    PubMed
  86. Feighner
    JP
    ,  
    Gardner
    EA
    ,  
    Johnston
    JA
    ,  
    Batey
    SR
    ,  
    Khayrallah
    MA
    ,  
    Ascher
    JA
    .  
    Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    J Clin Psychiatry
    1991
    52
    329
    35
    PubMed
    PubMed
  87. Hicks
    JA
    ,  
    Argyropoulos
    SV
    ,  
    Rich
    AS
    ,  
    Nash
    JR
    ,  
    Bell
    CJ
    ,  
    Edwards
    C
    .  
    Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
    Br J Psychiatry
    2002
    180
    528
    35
    PubMed
    CrossRef
    PubMed
  88. Kiev
    A
    ,  
    Feiger
    A
    .  
    A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
    J Clin Psychiatry
    1997
    58
    146
    52
    PubMed
    CrossRef
    PubMed
  89. Committee on Safety of Medicines. Report of the CSM expert working group on the safety of selective serotonin reuptake inhibitor antidepressants. London: Medicines and Healthcare products Regulatory Agency; 2004. Accessed at www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con019472.pdf on 2 December 2008.
  90. Fergusson
    D
    ,  
    Doucette
    S
    ,  
    Glass
    KC
    ,  
    Shapiro
    S
    ,  
    Healy
    D
    ,  
    Hebert
    P
    .  
    Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials.
    BMJ
    2005
    330
    396
    PubMed
    CrossRef
    PubMed
  91. Martinez
    C
    ,  
    Rietbrock
    S
    ,  
    Wise
    L
    ,  
    Ashby
    D
    ,  
    Chick
    J
    ,  
    Moseley
    J
    .  
    Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case##ndash##control study.
    BMJ
    2005
    330
    389
    PubMed
    CrossRef
    PubMed
  92. Gunnell
    D
    ,  
    Saperia
    J
    ,  
    Ashby
    D
    .  
    Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review.
    BMJ
    2005
    330
    385
    PubMed
    CrossRef
    PubMed
  93. Didham
    RC
    ,  
    McConnell
    DW
    ,  
    Blair
    HJ
    ,  
    Reith
    DM
    .  
    Suicide and self-harm following prescription of SSRIs and other antidepressants: confounding by indication.
    Br J Clin Pharmacol
    2005
    60
    519
    25
    PubMed
    CrossRef
    PubMed
  94. Jick
    H
    ,  
    Kaye
    JA
    ,  
    Jick
    SS
    .  
    Antidepressants and the risk of suicidal behaviors.
    JAMA
    2004
    292
    338
    43
    PubMed
    CrossRef
    PubMed
  95. Jick
    SS
    ,  
    Dean
    AD
    ,  
    Jick
    H
    .  
    Antidepressants and suicide.
    BMJ
    1995
    310
    215
    8
    PubMed
    CrossRef
    PubMed
  96. Jick
    H
    ,  
    Ulcickas
    M
    ,  
    Dean
    A
    .  
    Comparison of frequencies of suicidal tendencies among patients receiving fluoxetine, lofepramine, mianserin, or trazodone.
    Pharmacotherapy
    1992
    12
    451
    4
    PubMed
    PubMed
  97. Aursnes
    I
    ,  
    Tvete
    IF
    ,  
    Gaasemyr
    J
    ,  
    Natvig
    B
    .  
    Suicide attempts in clinical trials with paroxetine randomised against placebo.
    BMC Med
    2005
    3
    14
    PubMed
    CrossRef
    PubMed
  98. Khan
    A
    ,  
    Khan
    S
    ,  
    Kolts
    R
    ,  
    Brown
    WA
    .  
    Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.
    Am J Psychiatry
    2003
    160
    790
    2
    PubMed
    CrossRef
    PubMed
  99. Lopez-Iibor
    .  
    Reduced suicidality with paroxetine.
    Eur Psychiatry
    1993
    8
    17S
    19S
  100. Rocca
    P
    ,  
    Calvarese
    P
    ,  
    Faggiano
    F
    ,  
    Marchiaro
    L
    ,  
    Mathis
    F
    ,  
    Rivoira
    E
    .  
    Citalopram versus sertraline in late-life nonmajor clinically significant depression: a 1-year follow-up clinical trial.
    J Clin Psychiatry
    2005
    66
    360
    9
    PubMed
    CrossRef
    PubMed
  101. Kasper
    S
    ,  
    de Swart
    H
    ,  
    Friis Andersen
    H
    .  
    Escitalopram in the treatment of depressed elderly patients.
    Am J Geriatr Psychiatry
    2005
    13
    884
    91
    PubMed
    CrossRef
    PubMed
  102. Schne
    W
    ,  
    Ludwig
    M
    .  
    A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.
    J Clin Psychopharmacol
    1993
    13
    34S
    39S
    PubMed
    PubMed
  103. Geretsegger
    C
    ,  
    Bhmer
    F
    ,  
    Ludwig
    M
    .  
    Paroxetine in the elderly depressed patient: randomized comparison with fluoxetine of efficacy, cognitive and behavioural effects.
    Int Clin Psychopharmacol
    1994
    9
    25
    9
    PubMed
    CrossRef
    PubMed
  104. Cassano
    GB
    ,  
    Puca
    F
    ,  
    Scapicchio
    PL
    ,  
    Trabucchi
    M
    .  
    Italian Study Group on Depression in Elderly Patients
    Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients.
    J Clin Psychiatry
    2002
    63
    396
    402
    PubMed
    CrossRef
    PubMed
  105. Rossini
    D
    ,  
    Serretti
    A
    ,  
    Franchini
    L
    ,  
    Mandelli
    L
    ,  
    Smeraldi
    E
    ,  
    De Ronchi
    D
    .  
    Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial.
    J Clin Psychopharmacol
    2005
    25
    471
    5
    PubMed
    CrossRef
    PubMed
  106. Allard
    P
    ,  
    Gram
    L
    ,  
    Timdahl
    K
    ,  
    Behnke
    K
    ,  
    Hanson
    M
    ,  
    Sgaard
    J
    .  
    Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram.
    Int J Geriatr Psychiatry
    2004
    19
    1123
    30
    PubMed
    CrossRef
    PubMed
  107. Oslin
    DW
    ,  
    Ten Have
    TR
    ,  
    Streim
    JE
    ,  
    Datto
    CJ
    ,  
    Weintraub
    D
    ,  
    DiFilippo
    S
    .  
    Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.
    J Clin Psychiatry
    2003
    64
    875
    82
    PubMed
    CrossRef
    PubMed
  108. Thase
    ME
    ,  
    Entsuah
    R
    ,  
    Cantillon
    M
    ,  
    Kornstein
    SG
    .  
    Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions.
    J Womens Health (Larchmt)
    2005
    14
    609
    16
    PubMed
    CrossRef
    PubMed
  109. Entsuah
    AR
    ,  
    Huang
    H
    ,  
    Thase
    ME
    .  
    Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    J Clin Psychiatry
    2001
    62
    869
    77
    PubMed
    CrossRef
    PubMed
  110. Rapaport
    MH
    ,  
    Schneider
    LS
    ,  
    Dunner
    DL
    ,  
    Davies
    JT
    ,  
    Pitts
    CD
    .  
    Efficacy of controlled-release paroxetine in the treatment of late-life depression.
    J Clin Psychiatry
    2003
    64
    1065
    74
    PubMed
    CrossRef
    PubMed
  111. Tollefson
    GD
    ,  
    Bosomworth
    JC
    ,  
    Heiligenstein
    JH
    ,  
    Potvin
    JH
    ,  
    Holman
    S
    .  
    A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.
    Int Psychogeriatr
    1995
    7
    89
    104
    PubMed
    CrossRef
    PubMed
  112. Tollefson
    GD
    ,  
    Holman
    SL
    .  
    Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
    Int Clin Psychopharmacol
    1993
    8
    253
    9
    PubMed
    CrossRef
    PubMed
  113. Small
    GW
    ,  
    Birkett
    M
    ,  
    Meyers
    BS
    ,  
    Koran
    LM
    ,  
    Bystritsky
    A
    ,  
    Nemeroff
    CB
    .  
    Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group.
    J Am Geriatr Soc
    1996
    44
    1220
    5
    PubMed
    CrossRef
    PubMed
  114. Schneider
    LS
    ,  
    Nelson
    JC
    ,  
    Clary
    CM
    ,  
    Newhouse
    P
    ,  
    Krishnan
    KR
    ,  
    Shiovitz
    T
    .  
    Sertraline Elderly Depression Study Group
    An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.
    Am J Psychiatry
    2003
    160
    1277
    85
    PubMed
    CrossRef
    PubMed
  115. Sheikh
    JI
    ,  
    Cassidy
    EL
    ,  
    Doraiswamy
    PM
    ,  
    Salomon
    RM
    ,  
    Hornig
    M
    ,  
    Holland
    PJ
    .  
    Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness.
    J Am Geriatr Soc
    2004
    52
    86
    92
    PubMed
    CrossRef
    PubMed
  116. Roose
    SP
    ,  
    Sackeim
    HA
    ,  
    Krishnan
    KR
    ,  
    Pollock
    BG
    ,  
    Alexopoulos
    G
    ,  
    Lavretsky
    H
    .  
    Old-Old Depression Study Group
    Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.
    Am J Psychiatry
    2004
    161
    2050
    9
    PubMed
    CrossRef
    PubMed
  117. Kennedy
    SH
    ,  
    Eisfeld
    BS
    ,  
    Dickens
    SE
    ,  
    Bacchiochi
    JR
    ,  
    Bagby
    RM
    .  
    Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine.
    J Clin Psychiatry
    2000
    61
    276
    81
    PubMed
    CrossRef
    PubMed
  118. Morishita
    S
    ,  
    Arita
    S
    .  
    Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender.
    Eur Psychiatry
    2003
    18
    418
    20
    PubMed
    CrossRef
    PubMed
  119. Wagner
    GJ
    ,  
    Maguen
    S
    ,  
    Rabkin
    JG
    .  
    Ethnic differences in response to fluoxetine in a controlled trial with depressed HIV-positive patients.
    Psychiatr Serv
    1998
    49
    239
    40
    PubMed
    CrossRef
    PubMed
  120. Ferrando
    SJ
    ,  
    Goldman
    JD
    ,  
    Charness
    WE
    .  
    Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.
    Gen Hosp Psychiatry
    1997
    19
    89
    97
    PubMed
    CrossRef
    PubMed
  121. Rabkin
    JG
    ,  
    Wagner
    GJ
    ,  
    McElhiney
    MC
    ,  
    Rabkin
    R
    ,  
    Lin
    SH
    .  
    Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial.
    J Clin Psychopharmacol
    2004
    24
    379
    85
    PubMed
    CrossRef
    PubMed
  122. Rabkin
    JG
    ,  
    Wagner
    GJ
    ,  
    Rabkin
    R
    .  
    Fluoxetine treatment for depression in patients with HIV and AIDS: a randomized, placebo-controlled trial.
    Am J Psychiatry
    1999
    156
    101
    7
    PubMed
    CrossRef
    PubMed
  123. Gual
    A
    ,  
    Balcells
    M
    ,  
    Torres
    M
    ,  
    Madrigal
    M
    ,  
    Diez
    T
    ,  
    Serrano
    L
    .  
    Sertraline for the prevention of relapse in detoxicated alcohol dependent patients with a comorbid depressive disorder: a randomized, controlled trial.
    Alcohol Alcohol
    2003
    38
    619
    25
    PubMed
    CrossRef
    PubMed
  124. Hernandez-Avila
    CA
    ,  
    Modesto-Lowe
    V
    ,  
    Feinn
    R
    ,  
    Kranzler
    HR
    .  
    Nefazodone treatment of comorbid alcohol dependence and major depression.
    Alcohol Clin Exp Res
    2004
    28
    433
    40
    PubMed
    CrossRef
    PubMed
  125. Moak
    DH
    ,  
    Anton
    RF
    ,  
    Latham
    PK
    ,  
    Voronin
    KE
    ,  
    Waid
    RL
    ,  
    Durazo-Arvizu
    R
    .  
    Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial.
    J Clin Psychopharmacol
    2003
    23
    553
    62
    PubMed
    CrossRef
    PubMed
  126. Lyketsos
    CG
    ,  
    DelCampo
    L
    ,  
    Steinberg
    M
    ,  
    Miles
    Q
    ,  
    Steele
    CD
    ,  
    Munro
    C
    .  
    Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.
    Arch Gen Psychiatry
    2003
    60
    737
    46
    PubMed
    CrossRef
    PubMed
  127. Magai
    C
    ,  
    Kennedy
    G
    ,  
    Cohen
    CI
    ,  
    Gomberg
    D
    .  
    A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late-stage Alzheimer's disease.
    Am J Geriatr Psychiatry
    2000
    8
    66
    74
    PubMed
    CrossRef
    PubMed
  128. Nyth
    AL
    ,  
    Gottfries
    CG
    ,  
    Lyby
    K
    ,  
    Smedegaard-Andersen
    L
    ,  
    Gylding-Sabroe
    J
    ,  
    Kristensen
    M
    .  
    A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia.
    Acta Psychiatr Scand
    1992
    86
    138
    45
    PubMed
    CrossRef
    PubMed
  129. Roscoe
    JA
    ,  
    Morrow
    GR
    ,  
    Hickok
    JT
    ,  
    Mustian
    KM
    ,  
    Griggs
    JJ
    ,  
    Matteson
    SE
    .  
    Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy.
    Breast Cancer Res Treat
    2005
    89
    243
    9
    PubMed
    CrossRef
    PubMed
  130. Glassman
    AH
    ,  
    O'Connor
    CM
    ,  
    Califf
    RM
    ,  
    Swedberg
    K
    ,  
    Schwartz
    P
    ,  
    Bigger
    JT
    Jr
    .  
    Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group
    Sertraline treatment of major depression in patients with acute MI or unstable angina.
    JAMA
    2002
    288
    701
    9
    PubMed
    CrossRef
    PubMed
  131. Krishnan
    KR
    ,  
    Doraiswamy
    PM
    ,  
    Clary
    CM
    .  
    Clinical and treatment response characteristics of late-life depression associated with vascular disease: a pooled analysis of two multicenter trials with sertraline.
    Prog Neuropsychopharmacol Biol Psychiatry
    2001
    25
    347
    61
    PubMed
    CrossRef
    PubMed
  132. Strik
    JJ
    ,  
    Honig
    A
    ,  
    Lousberg
    R
    ,  
    Lousberg
    AH
    ,  
    Cheriex
    EC
    ,  
    Tuynman-Qua
    HG
    .  
    Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial.
    Psychosom Med
    2000
    62
    783
    9
    PubMed
    CrossRef
    PubMed
  133. Andersen
    G
    ,  
    Vestergaard
    K
    ,  
    Lauritzen
    L
    .  
    Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram.
    Stroke
    1994
    25
    1099
    104
    PubMed
    CrossRef
    PubMed
  134. Murray
    V
    ,  
    von Arbin
    M
    ,  
    Bartfai
    A
    ,  
    Berggren
    AL
    ,  
    Landtblom
    AM
    ,  
    Lundmark
    J
    .  
    Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression.
    J Clin Psychiatry
    2005
    66
    708
    16
    PubMed
    CrossRef
    PubMed
  135. Schmitz
    JM
    ,  
    Averill
    P
    ,  
    Stotts
    AL
    ,  
    Moeller
    FG
    ,  
    Rhoades
    HM
    ,  
    Grabowski
    J
    .  
    Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.
    Drug Alcohol Depend
    2001
    63
    207
    14
    PubMed
    CrossRef
    PubMed
  136. Petrakis
    I
    ,  
    Carroll
    KM
    ,  
    Nich
    C
    ,  
    Gordon
    L
    ,  
    Kosten
    T
    ,  
    Rounsaville
    B
    .  
    Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.
    Drug Alcohol Depend
    1998
    50
    221
    6
    PubMed
    CrossRef
    PubMed
  137. Bush
    DE
    ,  
    Ziegelstein
    RC
    ,  
    Patel
    UV
    ,  
    Thombs
    BD
    ,  
    Ford
    DE
    ,  
    Fauerbach
    JA
    .  
    Post-myocardial infarction depression.
    Evid Rep Technol Assess (Summ)
    2005
    1
    8
    PubMed
  138. .  
    Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision.
    Washington, DC
    American Psychiatric Assoc
    2000
  139. Kocsis
    JH
    ,  
    Zisook
    S
    ,  
    Davidson
    J
    ,  
    Shelton
    R
    ,  
    Yonkers
    K
    ,  
    Hellerstein
    DJ
    .  
    Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.
    Am J Psychiatry
    1997
    154
    390
    5
    PubMed
    CrossRef
    PubMed
  140. Thase
    ME
    ,  
    Fava
    M
    ,  
    Halbreich
    U
    ,  
    Kocsis
    JH
    ,  
    Koran
    L
    ,  
    Davidson
    J
    .  
    A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia.
    Arch Gen Psychiatry
    1996
    53
    777
    84
    PubMed
    CrossRef
    PubMed
  141. Williams
    JW
    Jr
    ,  
    Barrett
    J
    ,  
    Oxman
    T
    ,  
    Frank
    E
    ,  
    Katon
    W
    ,  
    Sullivan
    M
    .  
    Treatment of dysthymia and minor depression in primary care: A randomized, controlled trial in older adults.
    JAMA
    2000
    284
    1519
    26
    PubMed
    CrossRef
    PubMed
  142. Barrett
    JE
    ,  
    Williams
    JW
    Jr
    ,  
    Oxman
    TE
    ,  
    Frank
    E
    ,  
    Katon
    W
    ,  
    Sullivan
    M
    .  
    Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years.
    J Fam Pract
    2001
    50
    405
    12
    PubMed
    PubMed
  143. Judd
    LL
    ,  
    Rapaport
    MH
    ,  
    Yonkers
    KA
    ,  
    Rush
    AJ
    ,  
    Frank
    E
    ,  
    Thase
    ME
    .  
    Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder.
    Am J Psychiatry
    2004
    161
    1864
    71
    PubMed
    CrossRef
    PubMed
  144. Kavoussi
    RJ
    ,  
    Segraves
    RT
    ,  
    Hughes
    AR
    ,  
    Ascher
    JA
    ,  
    Johnston
    JA
    .  
    Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
    J Clin Psychiatry
    1997
    58
    532
    7
    PubMed
    CrossRef
    PubMed
  145. Cipriani
    A
    ,  
    Barbui
    C
    ,  
    Brambilla
    P
    ,  
    Furukawa
    TA
    ,  
    Hotopf
    M
    ,  
    Geddes
    JR
    .  
    Are all antidepressants really the same? The case of fluoxetine: a systematic review.
    J Clin Psychiatry
    2006
    67
    850
    64
    PubMed
    CrossRef
    PubMed
  146. Rush
    AJ
    ,  
    Trivedi
    MH
    ,  
    Wisniewski
    SR
    ,  
    Nierenberg
    AA
    ,  
    Stewart
    JW
    ,  
    Warden
    D
    .  
    Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.
    Am J Psychiatry
    2006
    163
    1905
    17
    PubMed
    CrossRef
    PubMed
  147. Aguglia
    E
    ,  
    Casacchia
    M
    ,  
    Cassano
    GB
    ,  
    Faravelli
    C
    ,  
    Ferrari
    G
    ,  
    Giordano
    P
    .  
    Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression.
    Int Clin Psychopharmacol
    1993
    8
    197
    202
    PubMed
    CrossRef
    PubMed
  148. Amini
    H
    ,  
    Aghayan
    S
    ,  
    Jalili
    SA
    ,  
    Akhondzadeh
    S
    ,  
    Yahyazadeh
    O
    ,  
    Pakravan-Nejad
    M
    .  
    Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    J Clin Pharm Ther
    2005
    30
    133
    8
    PubMed
    CrossRef
    PubMed
  149. Brown
    ES
    ,  
    Vigil
    L
    ,  
    Khan
    DA
    ,  
    Liggin
    JD
    ,  
    Carmody
    TJ
    ,  
    Rush
    AJ
    .  
    A randomized trial of citalopram versus placebo in outpatients with asthma and major depressive disorder: a proof of concept study.
    Biol Psychiatry
    2005
    58
    865
    70
    PubMed
    CrossRef
    PubMed
  150. Byerley
    WF
    ,  
    Reimherr
    FW
    ,  
    Wood
    DR
    ,  
    Grosser
    BI
    .  
    Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.
    J Clin Psychopharmacol
    1988
    8
    112
    5
    PubMed
    CrossRef
    PubMed
  151. Claghorn
    JL
    ,  
    Lesem
    MD
    .  
    A double-blind placebo-controlled study of Org 3770 in depressed outpatients.
    J Affect Disord
    1995
    34
    165
    71
    PubMed
    CrossRef
    PubMed
  152. Claghorn
    JL
    ,  
    Earl
    CQ
    ,  
    Walczak
    DD
    ,  
    Stoner
    KA
    ,  
    Wong
    LF
    ,  
    Kanter
    D
    .  
    Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.
    J Clin Psychopharmacol
    1996
    16
    113
    20
    PubMed
    CrossRef
    PubMed
  153. Claghorn
    JL
    .  
    The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients.
    J Clin Psychiatry
    1992
    53
    33
    5
    PubMed
    PubMed
  154. Cohn
    JB
    ,  
    Crowder
    JE
    ,  
    Wilcox
    CS
    ,  
    Ryan
    PJ
    .  
    A placebo- and imipramine-controlled study of paroxetine.
    Psychopharmacol Bull
    1990
    26
    185
    9
    PubMed
    PubMed
  155. Cohn
    JB
    ,  
    Wilcox
    CS
    .  
    Paroxetine in major depression: a double-blind trial with imipramine and placebo.
    J Clin Psychiatry
    1992
    53
    52
    6
    PubMed
    PubMed
  156. Corrigan
    MH
    ,  
    Denahan
    AQ
    ,  
    Wright
    CE
    ,  
    Ragual
    RJ
    ,  
    Evans
    DL
    .  
    Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.
    Depress Anxiety
    2000
    11
    58
    65
    PubMed
    CrossRef
    PubMed
  157. Croft
    H
    ,  
    Houser
    TL
    ,  
    Jamerson
    BD
    ,  
    Leadbetter
    R
    ,  
    Bolden-Watson
    C
    ,  
    Donahue
    R
    .  
    Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.
    Clin Ther
    2002
    24
    662
    72
    PubMed
    CrossRef
    PubMed
  158. Dunbar
    GC
    ,  
    Cohn
    JB
    ,  
    Fabre
    LF
    ,  
    Feighner
    JP
    ,  
    Fieve
    RR
    ,  
    Mendels
    J
    .  
    A comparison of paroxetine, imipramine and placebo in depressed out-patients.
    Br J Psychiatry
    1991
    159
    394
    8
    PubMed
    CrossRef
    PubMed
  159. Dunbar
    GC
    ,  
    Claghorn
    JL
    ,  
    Kiev
    A
    ,  
    Rickels
    K
    ,  
    Smith
    WT
    .  
    A comparison of paroxetine and placebo in depressed outpatients.
    Acta Psychiatr Scand
    1993
    87
    302
    5
    PubMed
    CrossRef
    PubMed
  160. Elliott
    AJ
    ,  
    Uldall
    KK
    ,  
    Bergam
    K
    ,  
    Russo
    J
    ,  
    Claypoole
    K
    ,  
    Roy-Byrne
    PP
    .  
    Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients.
    Am J Psychiatry
    1998
    155
    367
    72
    PubMed
    PubMed
  161. Evans
    M
    ,  
    Hammond
    M
    ,  
    Wilson
    K
    ,  
    Lye
    M
    ,  
    Copeland
    J
    .  
    Placebo-controlled treatment trial of depression in elderly physically ill patients.
    Int J Geriatr Psychiatry
    1997
    12
    817
    24
    PubMed
    CrossRef
    PubMed
  162. Fabre
    L
    ,  
    Birkhimer
    LJ
    ,  
    Zaborny
    BA
    ,  
    Wong
    LF
    ,  
    Kapik
    BM
    .  
    Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Int Clin Psychopharmacol
    1996
    11
    119
    27
    PubMed
    PubMed
  163. Fabre
    LF
    ,  
    Abuzzahab
    FS
    ,  
    Amin
    M
    ,  
    Claghorn
    JL
    ,  
    Mendels
    J
    ,  
    Petrie
    WM
    .  
    Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.
    Biol Psychiatry
    1995
    38
    592
    602
    PubMed
    CrossRef
    PubMed
  164. Fabre
    LF
    .  
    A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.
    J Clin Psychiatry
    1992
    53
    40
    3
    PubMed
    PubMed
  165. Fabre
    LF
    ,  
    Putman
    HP
    3rd
    .  
    A fixed-dose clinical trial of fluoxetine in outpatients with major depression.
    J Clin Psychiatry
    1987
    48
    406
    8
    PubMed
    PubMed
  166. Falk
    WE
    ,  
    Rosenbaum
    JF
    ,  
    Otto
    MW
    ,  
    Zusky
    PM
    ,  
    Weilburg
    JB
    ,  
    Nixon
    RA
    .  
    Fluoxetine versus trazodone in depressed geriatric patients.
    J Geriatr Psychiatry Neurol
    1989
    2
    208
    14
    PubMed
    CrossRef
    PubMed
  167. Fava
    M
    ,  
    Alpert
    J
    ,  
    Nierenberg
    AA
    ,  
    Mischoulon
    D
    ,  
    Otto
    MW
    ,  
    Zajecka
    J
    .  
    A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
    J Clin Psychopharmacol
    2005
    25
    441
    7
    PubMed
    CrossRef
    PubMed
  168. Fava
    M
    ,  
    Mulroy
    R
    ,  
    Alpert
    J
    ,  
    Nierenberg
    AA
    ,  
    Rosenbaum
    JF
    .  
    Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.
    Am J Psychiatry
    1997
    154
    1760
    2
    PubMed
    CrossRef
    PubMed
  169. Feighner
    JP
    .  
    A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients.
    Int Clin Psychopharmacol
    1992
    6
    31
    5
    PubMed
    CrossRef
    PubMed
  170. Feighner
    JP
    ,  
    Boyer
    WF
    .  
    Paroxetine in the treatment of depression: a comparison with imipramine and placebo.
    J Clin Psychiatry
    1992
    53
    44
    7
    PubMed
    PubMed
  171. Feighner
    JP
    ,  
    Cohn
    JB
    ,  
    Fabre
    LF
    Jr
    ,  
    Fieve
    RR
    ,  
    Mendels
    J
    ,  
    Shrivastava
    RK
    .  
    A study comparing paroxetine placebo and imipramine in depressed patients.
    J Affect Disord
    1993
    28
    71
    9
    PubMed
    CrossRef
    PubMed
  172. Feighner
    J
    ,  
    Targum
    SD
    ,  
    Bennett
    ME
    ,  
    Roberts
    DL
    ,  
    Kensler
    TT
    ,  
    D'Amico
    MF
    .  
    A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression.
    J Clin Psychiatry
    1998
    59
    246
    53
    PubMed
    CrossRef
    PubMed
  173. Flament
    MF
    ,  
    Lane
    R
    .  
    Acute antidepressant response to fluoxetine and sertraline in psychiatric outpatients with psychomotor agitation.
    Int J Psychiatry Clin Pract
    2001
    5
    103
    9
    CrossRef
    PubMed
  174. Gilaberte
    I
    ,  
    Montejo
    AL
    ,  
    de la Gandara
    J
    ,  
    Perez-Sola
    V
    ,  
    Bernardo
    M
    ,  
    Massana
    J
    .  
    Fluoxetine Long-Term Study Group
    Fluoxetine in the prevention of depressive recurrences: a double-blind study.
    J Clin Psychopharmacol
    2001
    21
    417
    24
    PubMed
    CrossRef
    PubMed
  175. Grigoriadis
    S
    ,  
    Kennedy
    SH
    ,  
    Bagby
    RM
    .  
    A comparison of antidepressant response in younger and older women.
    J Clin Psychopharmacol
    2003
    23
    405
    7
    PubMed
    CrossRef
    PubMed
  176. Glseren
    L
    ,  
    Glseren
    S
    ,  
    Hekimsoy
    Z
    ,  
    Mete
    L
    .  
    Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients.
    Arch Med Res
    2005
    36
    159
    65
    PubMed
    CrossRef
    PubMed
  177. Kennedy
    SH
    ,  
    Fulton
    KA
    ,  
    Bagby
    RM
    ,  
    Greene
    AL
    ,  
    Cohen
    NL
    ,  
    Rafi-Tari
    S
    .  
    Sexual function during bupropion or paroxetine treatment of major depressive disorder.
    Can J Psychiatry
    2006
    51
    234
    42
    PubMed
    CrossRef
    PubMed
  178. Lapierre
    YD
    ,  
    Browne
    M
    ,  
    Horn
    E
    ,  
    Oyewumi
    LK
    ,  
    Sarantidis
    D
    ,  
    Roberts
    N
    .  
    Treatment of major affective disorder with fluvoxamine.
    J Clin Psychiatry
    1987
    48
    65
    8
    PubMed
    PubMed
  179. March
    JS
    ,  
    Kobak
    KA
    ,  
    Jefferson
    JW
    ,  
    Mazza
    J
    ,  
    Greist
    JH
    .  
    A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression.
    J Clin Psychiatry
    1990
    51
    200
    2
    PubMed
    PubMed
  180. McGrath
    PJ
    ,  
    Stewart
    JW
    ,  
    Janal
    MN
    ,  
    Petkova
    E
    ,  
    Quitkin
    FM
    ,  
    Klein
    DF
    .  
    A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression.
    Am J Psychiatry
    2000
    157
    344
    50
    PubMed
    CrossRef
    PubMed
  181. Mesters
    P
    ,  
    Cosyns
    P
    ,  
    Dejaiffe
    G
    ,  
    Fanielle
    J
    ,  
    Gilles
    C
    ,  
    Godderis
    J
    .  
    Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years.
    Int Clin Psychopharmacol
    1993
    8
    337
    40
    PubMed
    CrossRef
    PubMed
  182. Montgomery
    SA
    ,  
    Rasmussen
    JG
    ,  
    Lyby
    K
    ,  
    Connor
    P
    ,  
    Tanghj
    P
    .  
    Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression.
    Int Clin Psychopharmacol
    1992
    6
    65
    70
    PubMed
    CrossRef
    PubMed
  183. Muijen
    M
    ,  
    Roy
    D
    ,  
    Silverstone
    T
    ,  
    Mehmet
    A
    ,  
    Christie
    M
    .  
    A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients.
    Acta Psychiatr Scand
    1988
    78
    384
    90
    PubMed
    CrossRef
    PubMed
  184. Petracca
    GM
    ,  
    Chemerinski
    E
    ,  
    Starkstein
    SE
    .  
    A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease.
    Int Psychogeriatr
    2001
    13
    233
    40
    PubMed
    CrossRef
    PubMed
  185. Ravindran
    AV
    ,  
    Teehan
    MD
    ,  
    Bakish
    D
    .  
    The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression.
    Hum Psychopharmacol
    1995
    10
    4
    273
    281
    CrossRef
  186. Reimherr
    FW
    ,  
    Cunningham
    LA
    ,  
    Batey
    SR
    ,  
    Johnston
    JA
    ,  
    Ascher
    JA
    .  
    A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients.
    Clin Ther
    1998
    20
    505
    16
    PubMed
    CrossRef
    PubMed
  187. Rickels
    K
    ,  
    Schweizer
    E
    ,  
    Clary
    C
    ,  
    Fox
    I
    ,  
    Weise
    C
    .  
    Nefazodone and imipramine in major depression: a placebo-controlled trial.
    Br J Psychiatry
    1994
    164
    802
    5
    PubMed
    CrossRef
    PubMed
  188. Rickels
    K
    ,  
    Case
    WG
    .  
    Trazodone in depressed outpatients.
    Am J Psychiatry
    1982
    139
    803
    6
    PubMed
    CrossRef
    PubMed
  189. Rickels
    K
    ,  
    Amsterdam
    J
    ,  
    Clary
    C
    ,  
    Fox
    I
    ,  
    Schweizer
    E
    ,  
    Weise
    C
    .  
    The efficacy and safety of paroxetine compared with placebo in outpatients with major depression.
    J Clin Psychiatry
    1992
    53
    30
    2
    PubMed
    PubMed
  190. Rosenbaum
    JF
    ,  
    Fava
    M
    ,  
    Hoog
    SL
    ,  
    Ascroft
    RC
    ,  
    Krebs
    WB
    .  
    Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.
    Biol Psychiatry
    1998
    44
    77
    87
    PubMed
    CrossRef
    PubMed
  191. Roth
    D
    ,  
    Mattes
    J
    ,  
    Sheehan
    KH
    ,  
    Sheehan
    DV
    .  
    A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression.
    Prog Neuropsychopharmacol Biol Psychiatry
    1990
    14
    929
    39
    PubMed
    CrossRef
    PubMed
  192. Roy-Byrne
    PP
    ,  
    Pages
    KP
    ,  
    Russo
    JE
    ,  
    Jaffe
    C
    ,  
    Blume
    AW
    ,  
    Kingsley
    E
    .  
    Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial.
    J Clin Psychopharmacol
    2000
    20
    129
    36
    PubMed
    CrossRef
    PubMed
  193. Rudolph
    RL
    ,  
    Fabre
    LF
    ,  
    Feighner
    JP
    ,  
    Rickels
    K
    ,  
    Entsuah
    R
    ,  
    Derivan
    AT
    .  
    A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression.
    J Clin Psychiatry
    1998
    59
    116
    22
    PubMed
    CrossRef
    PubMed
  194. Schweizer
    E
    ,  
    Weise
    C
    ,  
    Clary
    C
    ,  
    Fox
    I
    ,  
    Rickels
    K
    .  
    Placebo-controlled trial of venlafaxine for the treatment of major depression.
    J Clin Psychopharmacol
    1991
    11
    233
    6
    PubMed
    CrossRef
    PubMed
  195. Smith
    WT
    ,  
    Glaudin
    V
    ,  
    Panagides
    J
    ,  
    Gilvary
    E
    .  
    Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder.
    Psychopharmacol Bull
    1990
    26
    191
    6
    PubMed
    PubMed
  196. Smith
    WT
    ,  
    Glaudin
    V
    .  
    A placebo-controlled trial of paroxetine in the treatment of major depression.
    J Clin Psychiatry
    1992
    53
    36
    9
    PubMed
    PubMed
  197. Stahl
    SM
    .  
    Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
    Biol Psychiatry
    2000
    48
    894
    901
    PubMed
    CrossRef
    PubMed
  198. Thase
    ME
    ,  
    Entsuah
    AR
    ,  
    Rudolph
    RL
    .  
    Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors.
    Br J Psychiatry
    2001
    178
    234
    41
    PubMed
    CrossRef
    PubMed
  199. Tollefson
    GD
    ,  
    Rampey
    AH
    Jr
    ,  
    Beasley
    CM
    Jr
    ,  
    Enas
    GG
    ,  
    Potvin
    JH
    .  
    Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
    J Clin Psychopharmacol
    1994
    14
    163
    9
    PubMed
    PubMed
  200. Beasley
    CM
    Jr
    ,  
    Dornseif
    BE
    ,  
    Bosomworth
    JC
    ,  
    Sayler
    ME
    ,  
    Rampey
    AH
    Jr
    ,  
    Heiligenstein
    JH
    .  
    Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression.
    BMJ
    1991
    303
    685
    92
    PubMed
    CrossRef
    PubMed
  201. Vartiainen
    H
    ,  
    Leinonen
    E
    .  
    Double-blind study of mirtazapine and placebo in hospitalized patients with major depression.
    Eur Neuropsychopharmacol
    1994
    4
    145
    50
    PubMed
    CrossRef
    PubMed
  202. Wade
    A
    ,  
    Crawford
    GM
    ,  
    Angus
    M
    ,  
    Wilson
    R
    ,  
    Hamilton
    L
    .  
    A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care.
    Int Clin Psychopharmacol
    2003
    18
    133
    41
    PubMed
    PubMed
  203. Wernicke
    JF
    ,  
    Dunlop
    SR
    ,  
    Dornseif
    BE
    ,  
    Zerbe
    RL
    .  
    Fixed-dose fluoxetine therapy for depression.
    Psychopharmacol Bull
    1987
    23
    164
    8
    PubMed
    PubMed
  204. Winokur
    A
    ,  
    DeMartinis
    NA
    3rd
    ,  
    McNally
    DP
    ,  
    Gary
    EM
    ,  
    Cormier
    JL
    ,  
    Gary
    KA
    .  
    Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
    J Clin Psychiatry
    2003
    64
    1224
    9
    PubMed
    CrossRef
    PubMed
  205. Zanardi
    R
    ,  
    Franchini
    L
    ,  
    Gasperini
    M
    ,  
    Perez
    J
    ,  
    Smeraldi
    E
    .  
    Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.
    Am J Psychiatry
    1996
    153
    1631
    3
    PubMed
    CrossRef
    PubMed
  206. Baldwin
    DS
    ,  
    Cooper
    JA
    ,  
    Huusom
    AK
    ,  
    Hindmarch
    I
    .  
    A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder.
    Int Clin Psychopharmacol
    2006
    21
    159
    69
    PubMed
    CrossRef
    PubMed
  207. Boulenger
    JP
    ,  
    Huusom
    AK
    ,  
    Florea
    I
    ,  
    Baekdal
    T
    ,  
    Sarchiapone
    M
    .  
    A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Curr Med Res Opin
    2006
    22
    1331
    41
    PubMed
    CrossRef
    PubMed
  208. Dalery
    J
    ,  
    Honig
    A
    .  
    Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
    Hum Psychopharmacol
    2003
    18
    379
    84
    PubMed
    CrossRef
    PubMed
  209. De Wilde
    J
    ,  
    Spiers
    R
    ,  
    Mertens
    C
    ,  
    Bartholom
    F
    ,  
    Schotte
    G
    ,  
    Leyman
    S
    .  
    A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
    Acta Psychiatr Scand
    1993
    87
    141
    5
    PubMed
    CrossRef
    PubMed
  210. Ekselius
    L
    ,  
    von Knorring
    L
    .  
    Effect on sexual function of long-term treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care.
    J Clin Psychopharmacol
    2001
    21
    154
    60
    PubMed
    CrossRef
    PubMed
  211. Fava
    M
    ,  
    Judge
    R
    ,  
    Hoog
    SL
    ,  
    Nilsson
    ME
    ,  
    Koke
    SC
    .  
    Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
    J Clin Psychiatry
    2000
    61
    863
    7
    PubMed
    CrossRef
    PubMed
  212. Haffmans
    PM
    ,  
    Timmerman
    L
    ,  
    Hoogduin
    CA
    .  
    Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Int Clin Psychopharmacol
    1996
    11
    157
    64
    PubMed
    CrossRef
    PubMed
  213. Nemeroff
    CB
    ,  
    Ninan
    PT
    ,  
    Ballenger
    J
    ,  
    Lydiard
    RB
    ,  
    Feighner
    J
    ,  
    Patterson
    WM
    .  
    Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients.
    Depression
    1995
    3
    163
    9
    CrossRef
  214. Patris
    M
    ,  
    Bouchard
    JM
    ,  
    Bougerol
    T
    ,  
    Charbonnier
    JF
    ,  
    Chevalier
    JF
    ,  
    Clerc
    G
    .  
    Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice.
    Int Clin Psychopharmacol
    1996
    11
    129
    36
    PubMed
    PubMed
  215. Rapaport
    M
    ,  
    Coccaro
    E
    ,  
    Sheline
    Y
    ,  
    Perse
    T
    ,  
    Holland
    P
    ,  
    Fabre
    L
    .  
    A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    J Clin Psychopharmacol
    1996
    16
    373
    8
    PubMed
    CrossRef
    PubMed
  216. Tignol
    J
    .  
    A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression.
    J Clin Psychopharmacol
    1993
    13
    18S
    22S
    PubMed
    CrossRef
    PubMed
  217. Ventura
    D
    ,  
    Armstrong
    EP
    ,  
    Skrepnek
    GH
    ,  
    Haim Erder
    M
    .  
    Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Curr Med Res Opin
    2007
    23
    245
    50
    PubMed
    CrossRef
    PubMed
  218. Balls
    C
    ,  
    Quiros
    G
    ,  
    De Flores
    T
    ,  
    de la Torre
    J
    ,  
    Palao
    D
    ,  
    Rojo
    L
    .  
    The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia.
    Int Clin Psychopharmacol
    2000
    15
    43
    8
    PubMed
    CrossRef
    PubMed
  219. Goldstein
    DJ
    ,  
    Mallinckrodt
    C
    ,  
    Lu
    Y
    ,  
    Demitrack
    MA
    .  
    Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    J Clin Psychiatry
    2002
    63
    225
    31
    PubMed
    CrossRef
    PubMed
  220. Mehtonen
    OP
    ,  
    Sgaard
    J
    ,  
    Roponen
    P
    ,  
    Behnke
    K
    .  
    Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group.
    J Clin Psychiatry
    2000
    61
    95
    100
    PubMed
    CrossRef
    PubMed
  221. Montgomery
    SA
    ,  
    Huusom
    AK
    ,  
    Bothmer
    J
    .  
    A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder.
    Neuropsychobiology
    2004
    50
    57
    64
    PubMed
    CrossRef
    PubMed
  222. Nierenberg
    AA
    ,  
    Greist
    JH
    ,  
    Mallinckrodt
    CH
    ,  
    Prakash
    A
    ,  
    Sambunaris
    A
    ,  
    Tollefson
    GD
    .  
    Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Curr Med Res Opin
    2007
    23
    401
    16
    PubMed
    CrossRef
    PubMed
  223. Schatzberg
    A
    ,  
    Roose
    S
    .  
    A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Am J Geriatr Psychiatry
    2006
    14
    361
    70
    PubMed
    CrossRef
    PubMed
  224. Shelton
    RC
    ,  
    Haman
    KL
    ,  
    Rapaport
    MH
    ,  
    Kiev
    A
    ,  
    Smith
    WT
    ,  
    Hirschfeld
    RM
    .  
    A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
    J Clin Psychiatry
    2006
    67
    1674
    81
    PubMed
    CrossRef
    PubMed
  225. Silverstone
    PH
    ,  
    Ravindran
    A
    .  
    Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    J Clin Psychiatry
    1999
    60
    22
    8
    PubMed
    CrossRef
    PubMed
  226. Feiger
    A
    ,  
    Kiev
    A
    ,  
    Shrivastava
    RK
    ,  
    Wisselink
    PG
    ,  
    Wilcox
    CS
    .  
    Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction.
    J Clin Psychiatry
    1996
    57
    53
    62
    PubMed
    PubMed
  227. Kasper
    S
    ,  
    Olivieri
    L
    ,  
    Di Loreto
    G
    ,  
    Dionisio
    P
    .  
    A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder.
    Curr Med Res Opin
    2005
    21
    1139
    46
    PubMed
    CrossRef
    PubMed
  228. Munizza
    C
    ,  
    Olivieri
    L
    ,  
    Di Loreto
    G
    ,  
    Dionisio
    P
    .  
    A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Curr Med Res Opin
    2006
    22
    1703
    13
    PubMed
    CrossRef
    PubMed
  229. Perry
    PJ
    ,  
    Garvey
    MJ
    ,  
    Kelly
    MW
    ,  
    Cook
    BL
    ,  
    Dunner
    FJ
    ,  
    Winokur
    G
    .  
    A comparative trial of fluoxetine versus trazodone in outpatients with major depression.
    J Clin Psychiatry
    1989
    50
    290
    4
    PubMed
    PubMed
  230. Halikas
    JA
    .  
    Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients.
    Hum Psychopharmacol
    1995
    10
    S125
    33
    CrossRef
  231. van Moffaert
    M
    ,  
    de Wilde
    J
    ,  
    Vereecken
    A
    ,  
    Dierick
    M
    ,  
    Evrard
    JL
    ,  
    Wilmotte
    J
    .  
    Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression.
    Int Clin Psychopharmacol
    1995
    10
    3
    9
    PubMed
    CrossRef
    PubMed
  232. Weisler
    RH
    ,  
    Johnston
    JA
    ,  
    Lineberry
    CG
    ,  
    Samara
    B
    ,  
    Branconnier
    RJ
    ,  
    Billow
    AA
    .  
    Comparison of bupropion and trazodone for the treatment of major depression.
    J Clin Psychopharmacol
    1994
    14
    170
    9
    PubMed
    CrossRef
    PubMed
  233. Weihs
    KL
    ,  
    Houser
    TL
    ,  
    Batey
    SR
    ,  
    Ascher
    JA
    ,  
    Bolden-Watson
    C
    ,  
    Donahue
    RM
    .  
    Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression.
    Biol Psychiatry
    2002
    51
    753
    61
    PubMed
    CrossRef
    PubMed
  234. Hochstrasser
    B
    ,  
    Isaksen
    PM
    ,  
    Koponen
    H
    ,  
    Lauritzen
    L
    ,  
    Mahnert
    FA
    ,  
    Rouillon
    F
    .  
    Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
    Br J Psychiatry
    2001
    178
    304
    10
    PubMed
    CrossRef
    PubMed
  235. Klysner
    R
    ,  
    Bent-Hansen
    J
    ,  
    Hansen
    HL
    ,  
    Lunde
    M
    ,  
    Pleidrup
    E
    ,  
    Poulsen
    DL
    .  
    Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy.
    Br J Psychiatry
    2002
    181
    29
    35
    PubMed
    CrossRef
    PubMed
  236. Kornstein
    SG
    ,  
    Bose
    A
    ,  
    Li
    D
    ,  
    Saikali
    KG
    ,  
    Gandhi
    C
    .  
    Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
    J Clin Psychiatry
    2006
    67
    1767
    75
    PubMed
    CrossRef
    PubMed
  237. Montgomery
    SA
    ,  
    Rasmussen
    JG
    .  
    Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression.
    Int Clin Psychopharmacol
    1992
    6
    71
    3
    PubMed
    CrossRef
    PubMed
  238. Robert
    P
    ,  
    Montgomery
    SA
    .  
    Citalopram in doses of 20-60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study.
    Int Clin Psychopharmacol
    1995
    10
    29
    35
    PubMed
    CrossRef
    PubMed
  239. Rapaport
    MH
    ,  
    Bose
    A
    ,  
    Zheng
    H
    .  
    Escitalopram continuation treatment prevents relapse of depressive episodes.
    J Clin Psychiatry
    2004
    65
    44
    9
    PubMed
    CrossRef
    PubMed
  240. Schmidt
    ME
    ,  
    Fava
    M
    ,  
    Robinson
    JM
    ,  
    Judge
    R
    .  
    The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder.
    J Clin Psychiatry
    2000
    61
    851
    7
    PubMed
    CrossRef
    PubMed
  241. Dinan
    TG
    .  
    Efficacy and safety of weekly treatment with enteric-coated fluoxetine in patients with major depressive disorder.
    J Clin Psychiatry
    2001
    62
    48
    52
    PubMed
    PubMed
  242. Reimherr
    FW
    ,  
    Amsterdam
    JD
    ,  
    Quitkin
    FM
    ,  
    Rosenbaum
    JF
    ,  
    Fava
    M
    ,  
    Zajecka
    J
    .  
    Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.
    Am J Psychiatry
    1998
    155
    1247
    53
    PubMed
    CrossRef
    PubMed
  243. Michelson
    D
    ,  
    Amsterdam
    JD
    ,  
    Quitkin
    FM
    ,  
    Reimherr
    FW
    ,  
    Rosenbaum
    JF
    ,  
    Zajecka
    J
    .  
    Changes in weight during a 1-year trial of fluoxetine.
    Am J Psychiatry
    1999
    156
    1170
    6
    PubMed
    PubMed
  244. Terra
    JL
    ,  
    Montgomery
    SA
    .  
    Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study.
    Int Clin Psychopharmacol
    1998
    13
    55
    62
    PubMed
    CrossRef
    PubMed
  245. Thase
    ME
    ,  
    Nierenberg
    AA
    ,  
    Keller
    MB
    ,  
    Panagides
    J
    .  
    Relapse Prevention Study Group
    Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.
    J Clin Psychiatry
    2001
    62
    782
    8
    PubMed
    CrossRef
    PubMed
  246. Gelenberg
    AJ
    ,  
    Trivedi
    MH
    ,  
    Rush
    AJ
    ,  
    Thase
    ME
    ,  
    Howland
    R
    ,  
    Klein
    DN
    .  
    Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
    Biol Psychiatry
    2003
    54
    806
    17
    PubMed
    CrossRef
    PubMed
  247. Feiger
    AD
    ,  
    Bielski
    RJ
    ,  
    Bremner
    J
    ,  
    Heiser
    JF
    ,  
    Trivedi
    M
    ,  
    Wilcox
    CS
    .  
    Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression.
    Int Clin Psychopharmacol
    1999
    14
    19
    28
    PubMed
    CrossRef
    PubMed
  248. Claghorn
    JL
    ,  
    Feighner
    JP
    .  
    A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression.
    J Clin Psychopharmacol
    1993
    13
    23S
    27S
    PubMed
    CrossRef
    PubMed
  249. Montgomery
    SA
    ,  
    Dunbar
    G
    .  
    Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression.
    Int Clin Psychopharmacol
    1993
    8
    189
    95
    PubMed
    CrossRef
    PubMed
  250. Reynolds
    CF
    3rd
    ,  
    Dew
    MA
    ,  
    Pollock
    BG
    ,  
    Mulsant
    BH
    ,  
    Frank
    E
    ,  
    Miller
    MD
    .  
    Maintenance treatment of major depression in old age.
    N Engl J Med
    2006
    354
    1130
    8
    PubMed
    CrossRef
    PubMed
  251. Lpine
    JP
    ,  
    Caillard
    V
    ,  
    Bisserbe
    JC
    ,  
    Troy
    S
    ,  
    Hotton
    JM
    ,  
    Boyer
    P
    .  
    A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder.
    Am J Psychiatry
    2004
    161
    836
    42
    PubMed
    CrossRef
    PubMed
  252. Doogan
    DP
    ,  
    Caillard
    V
    .  
    Sertraline in the prevention of depression.
    Br J Psychiatry
    1992
    160
    217
    22
    PubMed
    CrossRef
    PubMed
  253. Keller
    MB
    ,  
    Kocsis
    JH
    ,  
    Thase
    ME
    ,  
    Gelenberg
    AJ
    ,  
    Rush
    AJ
    ,  
    Koran
    L
    .  
    Maintenance phase efficacy of sertraline for chronic depression: a randomized, controlled trial.
    JAMA
    1998
    280
    1665
    72
    PubMed
    CrossRef
    PubMed
  254. Kocsis
    JH
    ,  
    Schatzberg
    A
    ,  
    Rush
    AJ
    ,  
    Klein
    DN
    ,  
    Howland
    R
    ,  
    Gniwesch
    L
    .  
    Psychosocial outcomes following long-term, double-blind treatment of chronic depression with sertraline vs placebo.
    Arch Gen Psychiatry
    2002
    59
    723
    8
    PubMed
    CrossRef
    PubMed
  255. Lustman
    PJ
    ,  
    Clouse
    RE
    ,  
    Nix
    BD
    ,  
    Freedland
    KE
    ,  
    Rubin
    EH
    ,  
    McGill
    JB
    .  
    Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind, placebo-controlled trial.
    Arch Gen Psychiatry
    2006
    63
    521
    9
    PubMed
    CrossRef
    PubMed
  256. Wilson
    KC
    ,  
    Mottram
    PG
    ,  
    Ashworth
    L
    ,  
    Abou-Saleh
    MT
    .  
    Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study.
    Br J Psychiatry
    2003
    182
    492
    7
    PubMed
    CrossRef
    PubMed
  257. Venlafaxine 335 Study Group
    Venlafaxine versus placebo in the preventive treatment of recurrent major depression.
    J Clin Psychiatry
    2004
    65
    328
    36
    PubMed
    CrossRef
    PubMed
  258. Simon
    JS
    ,  
    Aguiar
    LM
    ,  
    Kunz
    NR
    ,  
    Lei
    D
    .  
    Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    J Psychiatr Res
    2004
    38
    249
    57
    PubMed
    CrossRef
    PubMed
  259. Joliat
    MJ
    ,  
    Schmidt
    ME
    ,  
    Fava
    M
    ,  
    Zhang
    S
    ,  
    Michelson
    D
    ,  
    Trapp
    NJ
    .  
    Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    J Clin Psychiatry
    2004
    65
    373
    8
    PubMed
    CrossRef
    PubMed
  260. Khan
    A
    ,  
    Upton
    GV
    ,  
    Rudolph
    RL
    ,  
    Entsuah
    R
    ,  
    Leventer
    SM
    .  
    The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group.
    J Clin Psychopharmacol
    1998
    18
    19
    25
    PubMed
    CrossRef
    PubMed
  261. Gillin
    JC
    ,  
    Rapaport
    M
    ,  
    Erman
    MK
    ,  
    Winokur
    A
    ,  
    Albala
    BJ
    .  
    A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial.
    J Clin Psychiatry
    1997
    58
    185
    92
    PubMed
    CrossRef
    PubMed
  262. Mallinckrodt
    CH
    ,  
    Watkin
    JG
    ,  
    Liu
    C
    ,  
    Wohlreich
    MM
    ,  
    Raskin
    J
    .  
    Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    BMC Psychiatry
    2005
    5
    1
    PubMed
    CrossRef
    PubMed
  263. Detke
    MJ
    ,  
    Lu
    Y
    ,  
    Goldstein
    DJ
    ,  
    Hayes
    JR
    ,  
    Demitrack
    MA
    .  
    Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
    J Clin Psychiatry
    2002
    63
    308
    15
    PubMed
    CrossRef
    PubMed
  264. Detke
    MJ
    ,  
    Lu
    Y
    ,  
    Goldstein
    DJ
    ,  
    McNamara
    RK
    ,  
    Demitrack
    MA
    .  
    Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression.
    J Psychiatr Res
    2002
    36
    383
    90
    PubMed
    CrossRef
    PubMed
  265. Brambilla
    P
    ,  
    Cipriani
    A
    ,  
    Hotopf
    M
    ,  
    Barbui
    C
    .  
    Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.
    Pharmacopsychiatry
    2005
    38
    69
    77
    PubMed
    CrossRef
    PubMed
  266. Greist
    J
    ,  
    McNamara
    RK
    ,  
    Mallinckrodt
    CH
    ,  
    Rayamajhi
    JN
    ,  
    Raskin
    J
    .  
    Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Clin Ther
    2004
    26
    1446
    55
    PubMed
    CrossRef
    PubMed
  267. Mackay
    FJ
    ,  
    Dunn
    NR
    ,  
    Wilton
    LV
    ,  
    Pearce
    GL
    ,  
    Freemantle
    SN
    ,  
    Mann
    RD
    .  
    A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies.
    Pharmacoepidemiol Drug Saf
    1997
    6
    235
    46
    PubMed
    CrossRef
    PubMed
  268. Mackay
    FR
    ,  
    Dunn
    NR
    ,  
    Martin
    RM
    ,  
    Pearce
    GL
    ,  
    Freemantle
    SN
    ,  
    Mann
    RD
    .  
    Newer antidepressants: a comparison of tolerability in general practice.
    Br J Gen Pract
    1999
    49
    892
    6
    PubMed
    PubMed
  269. Mackay
    FJ
    ,  
    Dunn
    NR
    ,  
    Mann
    RD
    .  
    Antidepressants and the serotonin syndrome in general practice.
    Br J Gen Pract
    1999
    49
    871
    4
    PubMed
    PubMed
  270. Meijer
    WE
    ,  
    Heerdink
    ER
    ,  
    van Eijk
    JT
    ,  
    Leufkens
    HG
    .  
    Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands.
    Pharmacoepidemiol Drug Saf
    2002
    11
    655
    62
    PubMed
    CrossRef
    PubMed
  271. Goldstein
    DJ
    ,  
    Hamilton
    SH
    ,  
    Masica
    DN
    ,  
    Beasley
    CM
    Jr
    .  
    Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
    J Clin Psychopharmacol
    1997
    17
    365
    9
    PubMed
    CrossRef
    PubMed
  272. Harto
    NE
    ,  
    Spera
    KF
    ,  
    Branconnier
    RJ
    .  
    Fluoxetine-induced reduction of body mass in patients with major depressive disorder.
    Psychopharmacol Bull
    1988
    24
    220
    3
    PubMed
    PubMed
  273. Judge
    R
    ,  
    Parry
    MG
    ,  
    Quail
    D
    ,  
    Jacobson
    JG
    .  
    Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment.
    Int Clin Psychopharmacol
    2002
    17
    217
    25
    PubMed
    CrossRef
    PubMed
  274. Perahia
    DG
    ,  
    Kajdasz
    DK
    ,  
    Desaiah
    D
    ,  
    Haddad
    PM
    .  
    Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    J Affect Disord
    2005
    89
    207
    12
    PubMed
    CrossRef
    PubMed
  275. Zajecka
    J
    ,  
    Fawcett
    J
    ,  
    Amsterdam
    J
    ,  
    Quitkin
    F
    ,  
    Reimherr
    F
    ,  
    Rosenbaum
    J
    .  
    Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study.
    J Clin Psychopharmacol
    1998
    18
    193
    7
    PubMed
    CrossRef
    PubMed
  276. Pedersen
    AG
    .  
    Escitalopram and suicidality in adult depression and anxiety.
    Int Clin Psychopharmacol
    2005
    20
    139
    43
    PubMed
    CrossRef
    PubMed
  277. Clayton
    AH
    ,  
    Pradko
    JF
    ,  
    Croft
    HA
    ,  
    Montano
    CB
    ,  
    Leadbetter
    RA
    ,  
    Bolden-Watson
    C
    .  
    Prevalence of sexual dysfunction among newer antidepressants.
    J Clin Psychiatry
    2002
    63
    357
    66
    PubMed
    CrossRef
    PubMed
  278. Clayton
    AH
    ,  
    Croft
    HA
    ,  
    Horrigan
    JP
    ,  
    Wightman
    DS
    ,  
    Krishen
    A
    ,  
    Richard
    NE
    .  
    Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    J Clin Psychiatry
    2006
    67
    736
    46
    PubMed
    CrossRef
    PubMed
  279. Delgado
    PL
    ,  
    Brannan
    SK
    ,  
    Mallinckrodt
    CH
    ,  
    Tran
    PV
    ,  
    McNamara
    RK
    ,  
    Wang
    F
    .  
    Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
    J Clin Psychiatry
    2005
    66
    686
    92
    PubMed
    CrossRef
    PubMed
  280. Ferguson
    JM
    ,  
    Shrivastava
    RK
    ,  
    Stahl
    SM
    ,  
    Hartford
    JT
    ,  
    Borian
    F
    ,  
    Ieni
    J
    .  
    Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline.
    J Clin Psychiatry
    2001
    62
    24
    9
    PubMed
    CrossRef
    PubMed
  281. Landn
    M
    ,  
    Hgberg
    P
    ,  
    Thase
    ME
    .  
    Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine.
    J Clin Psychiatry
    2005
    66
    100
    6
    PubMed
    CrossRef
    PubMed
  282. Nieuwstraten
    CE
    ,  
    Dolovich
    LR
    .  
    Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.
    Ann Pharmacother
    2001
    35
    1608
    13
    PubMed
    CrossRef
    PubMed
  283. Philipp
    M
    ,  
    Tiller
    JW
    ,  
    Baier
    D
    ,  
    Kohnen
    R
    .  
    Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.
    Eur Neuropsychopharmacol
    2000
    10
    305
    14
    PubMed
    CrossRef
    PubMed
  284. Dunner
    DL
    ,  
    Zisook
    S
    ,  
    Billow
    AA
    ,  
    Batey
    SR
    ,  
    Johnston
    JA
    ,  
    Ascher
    JA
    .  
    A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
    J Clin Psychiatry
    1998
    59
    366
    73
    PubMed
    CrossRef
    PubMed
  285. Johnston
    JA
    ,  
    Lineberry
    CG
    ,  
    Ascher
    JA
    ,  
    Davidson
    J
    ,  
    Khayrallah
    MA
    ,  
    Feighner
    JP
    .  
    A 102-center prospective study of seizure in association with bupropion.
    J Clin Psychiatry
    1991
    52
    450
    6
    PubMed
    PubMed
  286. Whyte
    IM
    ,  
    Dawson
    AH
    ,  
    Buckley
    NA
    .  
    Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants.
    QJM
    2003
    96
    369
    74
    PubMed
    CrossRef
    PubMed
  287. Thase
    ME
    .  
    Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients.
    J Clin Psychiatry
    1998
    59
    502
    8
    PubMed
    CrossRef
    PubMed
  288. Thase
    ME
    ,  
    Tran
    PV
    ,  
    Wiltse
    C
    ,  
    Pangallo
    BA
    ,  
    Mallinckrodt
    C
    ,  
    Detke
    MJ
    .  
    Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
    J Clin Psychopharmacol
    2005
    25
    132
    40
    PubMed
    CrossRef
    PubMed
  289. Buckley
    NA
    ,  
    McManus
    PR
    .  
    Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data.
    BMJ
    2002
    325
    1332
    3
    PubMed
    CrossRef
    PubMed
  290. Coogan
    PF
    ,  
    Palmer
    JR
    ,  
    Strom
    BL
    ,  
    Rosenberg
    L
    .  
    Use of selective serotonin reuptake inhibitors and the risk of breast cancer.
    Am J Epidemiol
    2005
    162
    835
    8
    PubMed
    CrossRef
    PubMed
  291. Kirby
    D
    ,  
    Harrigan
    S
    ,  
    Ames
    D
    .  
    Hyponatraemia in elderly psychiatric patients treated with selective serotonin reuptake inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit.
    Int J Geriatr Psychiatry
    2002
    17
    231
    7
    PubMed
    CrossRef
    PubMed
  292. Thapa
    PB
    ,  
    Gideon
    P
    ,  
    Cost
    TW
    ,  
    Milam
    AB
    ,  
    Ray
    WA
    .  
    Antidepressants and the risk of falls among nursing home residents.
    N Engl J Med
    1998
    339
    875
    82
    PubMed
    CrossRef
    PubMed
  293. Burt
    VK
    ,  
    Wohlreich
    MM
    ,  
    Mallinckrodt
    CH
    ,  
    Detke
    MJ
    ,  
    Watkin
    JG
    ,  
    Stewart
    DE
    .  
    Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years.
    Psychosomatics
    2005
    46
    345
    54
    PubMed
    CrossRef
    PubMed
  294. Kranzler
    HR
    ,  
    Mueller
    T
    ,  
    Cornelius
    J
    ,  
    Pettinati
    HM
    ,  
    Moak
    D
    ,  
    Martin
    PR
    .  
    Sertraline treatment of co-occurring alcohol dependence and major depression.
    J Clin Psychopharmacol
    2006
    26
    13
    20
    PubMed
    CrossRef
    PubMed
  295. Addington
    D
    ,  
    Addington
    J
    ,  
    Patten
    S
    ,  
    Remington
    G
    ,  
    Moamai
    J
    ,  
    Labelle
    A
    .  
    Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia.
    J Clin Psychopharmacol
    2002
    22
    20
    5
    PubMed
    CrossRef
    PubMed
  296. Burke
    WJ
    ,  
    McArthur-Miller
    DA
    .  
    Exploring treatment alternatives: weekly dosing of fluoxetine for the continuation phase of major depressive disorder.
    J Clin Psychiatry
    2001
    62
    38
    42
    PubMed
    PubMed
  297. Claghorn
    J
    .  
    A double-blind comparison of paroxetine and placebo in the treatment of depressed outpatients.
    Int Clin Psychopharmacol
    1992
    6
    25
    30
    PubMed
    CrossRef
    PubMed
  298. Claghorn
    JL
    ,  
    Kiev
    A
    ,  
    Rickels
    K
    ,  
    Smith
    WT
    ,  
    Dunbar
    GC
    .  
    Paroxetine versus placebo: a double-blind comparison in depressed patients.
    J Clin Psychiatry
    1992
    53
    434
    8
    PubMed
    PubMed
  299. Cohn
    CK
    ,  
    Robinson
    DS
    ,  
    Roberts
    DL
    ,  
    Schwiderski
    UE
    ,  
    O'Brien
    K
    ,  
    Ieni
    JR
    .  
    Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    J Clin Psychiatry
    1996
    57
    15
    8
    PubMed
    PubMed
  300. Cunningham
    LA
    .  
    Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group.
    Ann Clin Psychiatry
    1997
    9
    157
    64
    PubMed
    CrossRef
    PubMed
  301. Feighner
    JP
    ,  
    Over
    K
    .  
    Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
    J Clin Psychiatry
    1999
    60
    824
    30
    PubMed
    CrossRef
    PubMed
  302. Fontaine
    R
    ,  
    Ontiveros
    A
    ,  
    Elie
    R
    ,  
    Kensler
    TT
    ,  
    Roberts
    DL
    ,  
    Kaplita
    S
    .  
    A double-blind comparison of nefazodone, imipramine, and placebo in major depression.
    J Clin Psychiatry
    1994
    55
    234
    41
    PubMed
    PubMed
  303. Hypericum Depression Trial Study Group
    Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized, controlled trial.
    JAMA
    2002
    287
    1807
    14
    PubMed
    CrossRef
    PubMed
  304. Khan
    A
    ,  
    Fabre
    LF
    ,  
    Rudolph
    R
    .  
    Venlafaxine in depressed outpatients.
    Psychopharmacol Bull
    1991
    27
    141
    4
    PubMed
    PubMed
  305. Lineberry
    CG
    ,  
    Johnston
    JA
    ,  
    Raymond
    RN
    ,  
    Samara
    B
    ,  
    Feighner
    JP
    ,  
    Harto
    NE
    .  
    A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
    J Clin Psychiatry
    1990
    51
    194
    9
    PubMed
    PubMed
  306. Lydiard
    RB
    ,  
    Laird
    LK
    ,  
    Morton
    WA
    Jr
    ,  
    Steele
    TE
    ,  
    Kellner
    C
    ,  
    Laraia
    MT
    .  
    Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression.
    Psychopharmacol Bull
    1989
    25
    68
    70
    PubMed
    PubMed
  307. Lydiard
    RB
    ,  
    Stahl
    SM
    ,  
    Hertzman
    M
    ,  
    Harrison
    WM
    .  
    A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression.
    J Clin Psychiatry
    1997
    58
    484
    91
    PubMed
    CrossRef
    PubMed
  308. Mendels
    J
    ,  
    Johnston
    R
    ,  
    Mattes
    J
    ,  
    Riesenberg
    R
    .  
    Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study.
    Psychopharmacol Bull
    1993
    29
    169
    74
    PubMed
    PubMed
  309. Mendels
    J
    ,  
    Reimherr
    F
    ,  
    Marcus
    RN
    ,  
    Roberts
    DL
    ,  
    Francis
    RJ
    ,  
    Anton
    SF
    .  
    A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    J Clin Psychiatry
    1995
    56
    30
    6
    PubMed
    PubMed
  310. Olie
    JP
    ,  
    Gunn
    KP
    ,  
    Katz
    E
    .  
    A double-blind placebo-controlled multicentre study of sertraline in the acute and continuation treatment of major depression.
    Eur Psychiatry
    1997
    12
    34
    41
    CrossRef
    PubMed
  311. Reimherr
    FW
    ,  
    Chouinard
    G
    ,  
    Cohn
    CK
    ,  
    Cole
    JO
    ,  
    Itil
    TM
    ,  
    LaPierre
    YD
    .  
    Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.
    J Clin Psychiatry
    1990
    51
    18
    27
    PubMed
    PubMed
  312. Reimherr
    FW
    ,  
    Byerley
    WF
    ,  
    Ward
    MF
    ,  
    Lebegue
    BJ
    ,  
    Wender
    PH
    .  
    Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder.
    Psychopharmacol Bull
    1988
    24
    200
    5
    PubMed
    PubMed
  313. Rickels
    K
    ,  
    Amsterdam
    J
    ,  
    Clary
    C
    ,  
    Fox
    I
    ,  
    Schweizer
    E
    ,  
    Weise
    C
    .  
    A placebo-controlled, double-blind, clinical trial of paroxetine in depressed outpatients.
    Acta Psychiatr Scand Suppl
    1989
    350
    117
    23
    PubMed
    CrossRef
    PubMed
  314. Shrivastava
    RK
    ,  
    Shrivastava
    SH
    ,  
    Overweg
    N
    ,  
    Blumhardt
    CL
    .  
    A double-blind comparison of paroxetine, imipramine, and placebo in major depression.
    J Clin Psychiatry
    1992
    53
    48
    51
    PubMed
    PubMed
  315. Thase
    ME
    .  
    Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group.
    J Clin Psychiatry
    1997
    58
    393
    8
    PubMed
    CrossRef
    PubMed
  316. Heiligenstein
    JH
    ,  
    Ware
    JE
    Jr
    ,  
    Beusterien
    KM
    ,  
    Roback
    PJ
    ,  
    Andrejasich
    C
    ,  
    Tollefson
    GD
    .  
    Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.
    Int Psychogeriatr
    1995
    7
    125
    37
    PubMed
    CrossRef
    PubMed
  317. Trivedi
    MH
    ,  
    Pigotti
    TA
    ,  
    Perera
    P
    ,  
    Dillingham
    KE
    ,  
    Carfagno
    ML
    ,  
    Pitts
    CD
    .  
    Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
    J Clin Psychiatry
    2004
    65
    1356
    64
    PubMed
    CrossRef
    PubMed
  318. Wade
    A
    ,  
    Michael Lemming
    O
    ,  
    Bang Hedegaard
    K
    .  
    Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Int Clin Psychopharmacol
    2002
    17
    95
    102
    PubMed
    CrossRef
    PubMed
  319. Walczak
    DD
    ,  
    Apter
    JT
    ,  
    Halikas
    JA
    ,  
    Borison
    RL
    ,  
    Carman
    JS
    ,  
    Post
    GL
    .  
    The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients.
    Ann Clin Psychiatry
    1996
    8
    139
    51
    PubMed
    CrossRef
    PubMed
Figure 1.

Study flow diagram.

The number of included articles differs from the number of included studies because some studies have multiple publications.

Figure 2.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs) with other SSRIs

All estimates are based on network meta-analyses except for those marked with an asterisk or a dagger.

* Based on meta-analysis of head-to-head trials.

Based on indirect comparisons with meta-regression.

Figure 3.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs) with selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) and SSRIs with serotonin and norepinephrine reuptake inhibitors (SNRIs

All estimates are based on network meta-analyses except for those marked with an asterisk or a dagger.

* Based on meta-analysis of head-to-head trials.

Based on indirect comparisons with meta-regression.

Figure 4.

Relative benefit of response comparing selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SSNRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other second-generation antidepressants (ADs) with other second-generation ADs.

All estimates are based on network meta-analyses except for those marked with an asterisk.* Based on meta-analysis of head-to-head trials.

Table 1. Second-Generation Antidepressants Approved for Use in the United States

Table 1. Second-Generation Antidepressants Approved for Use in the United States

Appendix Table 1. Characteristics of Studies with Poor Internal Validity

Appendix Table 1. Characteristics of Studies with Poor Internal Validity

Appendix Table 2. Comparative Efficacy and Effectiveness Studies on Therapy for Major Depressive Disorder

Appendix Table 2. Comparative Efficacy and Effectiveness Studies on Therapy for Major Depressive Disorder

Appendix Table 3. Comparative Efficacy and Effectiveness Studies on Therapy for Dysthymia

Appendix Table 3. Comparative Efficacy and Effectiveness Studies on Therapy for Dysthymia

Appendix Table 4. Comparative Efficacy and Effectiveness Studies on Therapy for Subsyndromal Depressive Disorders

Appendix Table 4. Comparative Efficacy and Effectiveness Studies on Therapy for Subsyndromal Depressive Disorders

Appendix Table 5. Comparative Efficacy and Effectiveness Studies on Maintaining Remission and Preventing Relapse

Appendix Table 5. Comparative Efficacy and Effectiveness Studies on Maintaining Remission and Preventing Relapse

Appendix Table 6. Comparative Efficacy and Effectiveness Studies on Therapy for Recurrent and Treatment-Resistant Depression

Appendix Table 6. Comparative Efficacy and Effectiveness Studies on Therapy for Recurrent and Treatment-Resistant Depression

Appendix Table 7. Placebo-Controlled Studies of Relapse and Recurrence

Appendix Table 7. Placebo-Controlled Studies of Relapse and Recurrence

Appendix Table 8. Comparative Efficacy and Effectiveness Studies of Treatment in Adults with Major Depressive Disorder and Accompanying Symptoms

Appendix Table 8. Comparative Efficacy and Effectiveness Studies of Treatment in Adults with Major Depressive Disorder and Accompanying Symptoms

Appendix Table 9. Studies of Comparative Risk for Harms in Adults with Major Depressive Disorder

Appendix Table 9. Studies of Comparative Risk for Harms in Adults with Major Depressive Disorder

Appendix Table 10. Comparative Efficacy and Effectiveness Studies in Subgroups

Appendix Table 10. Comparative Efficacy and Effectiveness Studies in Subgroups

Appendix Table 11. Randomized, Placebo-Controlled Trials Included for Indirect Comparisons

Appendix Table 11. Randomized, Placebo-Controlled Trials Included for Indirect Comparisons

Table 2. Summary of Findings on General Effectiveness

Table 2. Summary of Findings on General Effectiveness

Table 3. Summary of Findings on Adverse Events: Comparative Risk for Harms

Table 3. Summary of Findings on Adverse Events: Comparative Risk for Harms

Table 4. Summary of Findings on Effectiveness in Subgroups

Table 4. Summary of Findings on Effectiveness in Subgroups

Table 5. Main Differences in Specific Adverse Events

Table 5. Main Differences in Specific Adverse Events

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Use of Drugs to Treat Depression: Guidelines from the American College of Physicians

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

1 Comment

Thomas E. Finucane

Johns Hopkins School of Medicine

December 5, 2008

Comparative Benefits and Harms of Second-Generation Antidepressants

Dr. Gartlehner and colleague's Background Paper on the comparative benefits and harms of second-generation antidepressants (SGAs) finds "no substantial differences in efficacy among these drugs," but notes that "other differences" may be relevant in choosing a drug (1). They also note that 69% of the studies were supported by the pharmaceutical industry, and for 21% of the studies, source of funding could not be determined. Drug company funding has a strong impact on the published literature. Companies naturally tend to seek publication of results favorable to their products (2).

Seven fair quality studies are cited, all showing that mirtazapine leads to higher weight gain than other SGAs; not shown is that all seven studies are sponsored by mirtazapine's vendor, Organon, and that three of the seven have at least one author who is a drug company employee. Without any good evidence, a market niche for mirtazapine has been created: depressed patients who are losing weight.

Writers of systematic reviews must decide how to weigh vendor-sponsored evidence, especially when most or all of the available evidence is vendor-sponsored. Here is a modest suggestion. In bibliographies, why not make the first initial of the first author scarlet if the paper is sponsored by the vendor? This would make it easy to see where the influence of industry might be suspected.

References

1. Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, Moore CG, et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med. 2008; 149: 734-750.

2. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: A review of publication and presentation. PLoS Med 2008; 5(11): e217: 0001-10.

Conflict of Interest:

None declared

PDF
Not Available
Citations
Citation

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians. Ann Intern Med. ;149:734–750. doi: 10.7326/0003-4819-149-10-200811180-00008

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2019

×
Permissions

Published: Ann Intern Med. 2008;149(10):734-750.

DOI: 10.7326/0003-4819-149-10-200811180-00008

©
2008 American College of Physicians
140 Citations

See Also

Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians
Use of Drugs to Treat Depression: Guidelines from the American College of Physicians
View MoreView Less

Related Articles

Using Second-Generation Antidepressants to Treat Depressive Disorders: A Clinical Practice Guideline from the American College of Physicians
Annals of Internal Medicine; 149 (10): 725-733
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
Annals of Internal Medicine; 143 (6): 415-426
Comparative Benefits and Harms of Second-Generation Antidepressants for Treating Major Depressive Disorder: An Updated Meta-analysis
Annals of Internal Medicine; 155 (11): 772-785
Update in General Internal Medicine
Annals of Internal Medicine; 127 (1): 43-51
View MoreView Less

Journal Club

Review: In major depressive disorder, antidepressant drugs improve short-term response compared with placebo
Annals of Internal Medicine; 168 (12): JC67
Sodium bicarb vs sodium chloride, and acetylcysteine vs placebo, did not differ for adverse events after angiography
Annals of Internal Medicine; 168 (4): JC22
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events
Annals of Internal Medicine; 167 (6): JC28
In older men, 5α-reductase inhibitors were linked to increased risk for self-harm and depression but not suicide
Annals of Internal Medicine; 167 (2): JC9
View MoreView Less

Related Point of Care

Depression
Annals of Internal Medicine; 165 (7): ITC49-ITC64
Depression
Annals of Internal Medicine; 152 (9): ITC5-1
Depression
Annals of Internal Medicine; 146 (9): ITC5-1
View MoreView Less

Related Topics

Guidelines
Pulmonary/Critical Care
Sleep Disorders

Guidelines, Pulmonary/Critical Care, Sleep Disorders.

PubMed Articles

Comparison of suicide attempts in individuals with major depressive disorder with and without history of subthreshold hypomania: A nationwide community sample of Korean adults✰,✰✰.
J Affect Disord 2019;
The Effects of Bullying in Depression on White Matter Integrity.
Behav Brain Res 2019.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×